WO2005000284A2 - Diaryl ureas for diseases mediated by pdgfr - Google Patents
Diaryl ureas for diseases mediated by pdgfr Download PDFInfo
- Publication number
- WO2005000284A2 WO2005000284A2 PCT/US2004/015653 US2004015653W WO2005000284A2 WO 2005000284 A2 WO2005000284 A2 WO 2005000284A2 US 2004015653 W US2004015653 W US 2004015653W WO 2005000284 A2 WO2005000284 A2 WO 2005000284A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- compound
- formula
- phenyl
- trifluoromethyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
Definitions
- PDGF platelet-derived growth factor
- PDGF was originally identified as the v-sis oncogene product of the simian sarcoma virus (Heldin, C.H., et al., J Cell Sci Suppl, 1985, 3, 65-76).
- This growth factor is made up of two peptide chains, referred to as A or B chains which share 60% homology in their primary amino acid sequence.
- the chains are disulfide cross linked to form the 30 kDa mature protein composed of either AA, BB or AB homo- or heterodimmers.
- PDGF is found at high levels in platelets, and is expressed by endothelial cells and vascular smooth muscle cells.
- PDGF binds with high affinity to the PDGF receptor, a 1106 amino acid 124 kDa transmembrane tyrosine kinase receptor (Heldin, C.H., A. Ostman, and L. Ronnstrand, Biochim Biophys Ada, 1998. 1378(1), 79-113).
- PDGFR is found as homo- or heterodimer chains which have 30% homology overall in their amino acid sequence and 64% homology between their kinase domains (Heldin, C.H., et al.. Embo J, 1988, 7(5), 1387-93).
- PDGFR is a member of a family of tyrosine kinase receptor with split kinase domains that includes VEGFR2 (KDR), c-Kit, and FLT3.
- the PDGF receptor is expressed primarily on fibroblast, smooth muscle cells, and pericytes and to a lesser extent on neurons, kidney mesangial, Leydig, and Schwann cells of the central nervous system.
- PDGF Upon binding to the receptor, PDGF induces receptor dimerization and undergoes auto- and trans-phosphorylation of tyrosine residues which increase the receptors' kinase activity and promotes the recruitment of downstream effectors through the activation of SH2 protein binding domains.
- a number of signaling molecules form complexes with activated PDGFR including PI-3 -kinase, phospholipase C-gamma, src and GAP (GTPase activating protein for p21-ras)
- PDGF activates the Rho signaling pathway inducing cell motility and migration, and through the activation of GAP, induces mitogenesis through the activation of p21-ras and the MAPK signaling pathway.
- the major function of PDGF is to facilitate and increase the rate of wound healing and to maintain blood vessel homeostasis (Baker, E.A. and D. J. Leaper, Wound Repair Regen, 2000. 8(5), 392-8; Yu, J., A. Moon, and H.R. Kim, Biochem Biophys Res Commun, 2001.
- PDGF is found at high concentrations in platelets and is a potent chemoattractant for fibroblast, smooth muscle cells, neutrophils and macrophages. In addition to its role in wound healing PDGF helps maintain vascular homeostasis. During the development of new blood vessels, PDGF recruits pericytes and smooth muscle cells that are needed for the structural integrity of the vessels. PDGF is thought to play a similar role during tumor neovascularization. As part of its role in angiogenesis, PDGF controls interstitial fluid pressure, regulating the permeability of vessels through its regulation of the interaction between connective tissue cells and the extracellular matrix.
- the PDGFR family of ligands is a set of homo- and heterodimeric ligands bound through a disulf ⁇ de bridge that can be found in three forms, AN, AB and BB.
- PDGF is a potent mitogen and chemotactic factor for a variety of mesenchymal cells, such as fibroblasts, vascular smooth muscle cells, glomerular mesangial cells and brain glial cells.
- PDGF has been implicated in a variety of pathological conditions, including cancer, atherosclerosis, restenosis, liver cirrhosis, pulmonary fibrosis, and glomerulonephritis.
- PDGF exerts its biological activity by binding to the PDGF receptor (PDGFR) inducing receptor dimerization.
- PDGFR PDGF receptor
- PDGF-AN induces only ⁇ / ⁇ receptor dimers
- PDGF-AB induces ⁇ / ⁇ and ⁇ / ⁇ receptor dimers
- PDGF-BB induces all three receptor dimer combinations.
- the PDGFR undergoes trans-phosphorylation on a tyrosine, activating it for intracellular signaling interactions essential that mediate changes in gene expression, cell migration and proliferation.
- vSMC vascular smooth muscle cells
- PDGF-BB may be a central chemotactic factor involved in wound healing following vascular trauma because it is both mitogenic for cultured vSCM through activation of PDGF receptors, and chemotactic through activation of PDGFR ⁇ .
- PDGF-BB acts predominantly as a chemotactic factor on vSMC. Injection of PDGF-BB has been shown to increase vSMC migration by greater than 10-fold, but proliferation by only
- Diarylureas are a class of serine-threonine kinase inhibitors as well as tyrosine kinase inhibitors well known in the art.
- the following publications illustrate their utility as an active ingredient in pharmaceutical compositions for the treatment of cancer, angiogenesis disorders, and inflammatory disorders:
- the present invention provides methods for treating, ameliorating, preventing, modulating, etc., conditions and diseases in humans and other mammals that are associated with and/or mediated by signal transduction pathways comprising platelet- derived growth factor receptor (PDGFR).
- PDGFR platelet- derived growth factor receptor
- Methods of the present invention especially provide for modulating diseases and conditions associated and/or mediated by PDGFR-beta.
- the present invention provides devices (e.g., stents and other materials in contact with blood and/or cells), compositions, and methods for treating, ameliorating, preventing, or modulating restenosis following angioplastic surgery or other invasive procedures that affect the vascular system, and graft rejection following transplantation of a donor tissue into a host.
- the methods can comprise, e.g., administering an aryl urea compound as described below, pharmaceutically- acceptable salts thereof, and prodrugs thereof.
- the compounds of the present invention can be utilized to treat any conditions or diseases mediated by PDGFR-beta, including any unwanted and/or deleterious consequence of an invasive procedures performed on the body, especially to the vascular system, including, but not limited to, angioplasty, atherectomy, arterial grafting, vessel wall stenting, and endarterectomy.
- the compounds can be applied directly to the affected area (e.g., in combination with a material or carrier designed to release the compound) or on a device or material that is introduced into the target site.
- aryl urea compounds employed in the methods of this invention comprise compounds of Formula I, pharmaceutically acceptable salts thereof, prodrugs thereof, and any active derivatives thereof, which are collectively referred to herein as the "compounds of the invention” and the like.
- Formula I is as follows:
- A is phenyl, optionally substituted with 1-3 substituents independently selected from the group consisting of C 1 -C 5 alkyl, C 1 -C 5 halogenoalkyl, up to perhaloalkyl, Ci-C 5 alkoxy, halogen, cyano, and nitro;
- A is a group of the formula:
- B is phenylene or naphthylene, optionally substituted with 1-3 substituents independently selected from the group consisting of C 1 -C 5 alkyl, C 1 -C 5 halogenoalkyl, up to perhaloalkyl, C1-C 5 alkoxy, halogen, cyano, and nitro;
- L is a linker selected from -O- or -S-;
- M is a pyridine ring, optionally substituted with C 1 -C 5 alkyl, C 1 -C 5 halogenoalkyl, up to perhaloalkyl, C 1 -C 5 alkoxy, halogen, and hydroxy; and
- Q is cyano, -C(0)-R ls or -C(0)-NR ⁇ R 2 , where Ri and R 2 are independently selected from H or lower alkyl.
- Suitable -Cs alkyl groups include methyl, ethyl, propyl, butyl, and pentyl, as well as branched isomers such as isopropyl, isobutyl, sec-butyl, tert-butyl, etc.
- C 1 -C 5 alkoxy means a straight or branched chain alkoxy grouphaving saturated carbon atoms which may be linear or branched with single or multiple branching, and includes such groups as methoxy, ethoxy, 7t-propoxy, isopropoxy, and the like. It also includes halogenated groups such as 2,2-dichloroethoxy, trifluoromethoxy, and the like.
- Suitable halogens include F, CI, Br, and or I, from one to per-substitution (i.e. all H atoms on a group replaced by a halogen atom) being possible where an alkyl group is substituted by halogen, mixed substitution of halogen atom types also being possible on a given moiety.
- Preferred halogens are CI, Br and F.
- C 1 -C 5 halogenoalkyl, up to perhaloalkyl includes alkyl groups having one or more alkyl hydrogens replaced with halogen, and alkyl groups having all alkyl hydrogens replaced by halogen.
- Examples include chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, and the like.
- any moiety can have up to the highest number of indicated substituents, and each substituent can be located at any available position on the moiety and can be attached through any available atom on the substituent.
- Any available position means any position on the moiety that is chemically accessible through means known in the art or taught herein and that does not create an unduly unstable molecule.
- each substituent is defined independently of any other substituent and can, accordingly, be the same or different.
- optionally substituted means that the moiety so modified may be either unsubstituted, or substituted with the identified substituent(s). It is understood that since M is pyridine, the term "hydroxy" as an optional pyridine substituent includes 2-, 3-, and 4-hydroxypyridine, but also includes those structures referred to in the art as 1-oxopyridine, 1-hydroxypyridme and pyridine N- oxide. Where the plural form of the word compounds, salts, and the like, is used herein, this is taken to mean also a single compound, salt, or the like.
- Compounds of the invention of particular interest include those of Formula I wherein B is phenylene, optionally substituted with halogen.
- Compounds of the invention of particular interest also include those of Formula I wherein L is -O-.
- Compounds of the invention of particular interest also include those of Formula I wherein A is phenyl, substituted with 1-3 substituents selected from the group consisting of -Cs alkyl, C1-C5 halogenoalkyl, up to perhaloalkyl, C 1 -C5 alkoxy, and halogen, or A is a group of the formula:
- Compounds of the invention of particular interest also include those of Formula I wherein: A is 4-chloro-3-trifluoromethylphenyl, 4-fluoro-3-trifluoromethylphenyl, 4- bromo-3-trifluoromethylphenyl, or 2,2,4,4-tetrafluoro-4H-benzo[ 1 ,3]dioxin-6-yl; B is phenylene, chlorophenylene or fluorophenylene; L is -O-; M is pyridine or 1-hydroxypyridine; and Q is cyano, C(0)- ⁇ H 2 , or C(0)-NHMe.
- Compounds of the invention of particular interest also include those selected from: N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4- pyridyl oxy)phenyl) urea, N-(4-bromo-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4- pyridyl oxy)phenyl) urea, ⁇ -(4-bromo-3-(trifluoromethyl)phenyl)- ⁇ '-(4-(2-(N-methylcarbamoyl)-4- pyridyl oxy)-2-chlorophenyl) urea, N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-carbamoyl-4- pyridyloxy)phenyl) urea
- a number of the compounds of Formula I possess asymmetric centers, depending on the location a nature of various substituents. These compounds can therefore exist in racemic and optically active forms as well as in the form of racemic or non-racemic mixtures thereof, and in the form of diastereomers and diastereomeric mixtures.
- Asymmetric carbon atoms may be present in the (R) or (S) configuration or (R,S) configuration. In certain instances, asymmetry may also be present due to restricted rotation about a given bond, for example, the central bond adjoining two substituted aromatic rings of the specified compounds.
- the optical isomers may be obtained by resolution of the racemic mixtures according to conventional processes, for example, by the formation of diastereoisomeric salts using an optically active acid or base.
- appropriate acids are tartaric, diacetyltartaric, dibenzoyltartaric, ditoluoyltartaric and camphorsulfonic acid.
- Mixtures of diastereoisomers can be separated into their individual diastereomers on the basis of their physical chemical differences by methods known to those skilled in the art, for example, by chromatography or fractional crystallization.
- the optically active bases or acids are liberated from the separated diastereomeric salts.
- optically active compounds of Formula (I) can likewise be obtained by utilizing optically active starting materials.
- the present invention encompasses any separated, isolated, pure or partially purified isomers or racemic mixtures of the compounds of formula I which possess PDGFR inhibitory activity, and/or an efficacy in modulating any of the diseases and/or conditions mentioned herein.
- stereoisomer is understood to encompass diastereoisomers, enantiomers, geometric isomers, etc.
- Preferred compounds are those with the absolute configuration of the compound of Formula I which produce the more desirable biological activity are also included within the scope of the present invention.
- the purification of said isomers and the separation of said isomeric mixtures can be accomplished by standard techniques known in the art.
- the phrase "substantially pure enantiomers” means that no more than about 5% w/w of the corresponding opposite enantiomer is present.
- Pharmaceutically-acceptable salts of these compounds, as well as commonly used prodrugs of these compounds are also within the scope of the invention.
- pharmaceutically acceptable salt refers to a relatively non-toxic, inorganic, or organic acid addition salt of a compound of the present invention. For example, see
- Suitable salts are especially the pharmaceutically acceptable salts of compounds of formula (I) or such as, for example, organic or inorganic acid addition salts of compounds of formula (I).
- Suitable acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cinnamate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2- hydroxyethanesulfonate, itaconate, lactate, maleate, mandelate, methanesulfonate, 2- naphthalenesulfonate, nicotinate, nitrate, oxalate, pamoate, pectinate, persulfate, 3- phenylprop
- Suitable inorganic acids include but are not limited to halogen acids (such as hydrochloric acid and hydrobromic acid), sulfuric acid, or phosphoric acid.
- Suitable organic acids include but are not limited to carboxylic, phosphonic, sulfonic, or sulfamic acids, with examples including acetic acid, propionic acid, octanoic acid, decanoic acid, trifluoroacetic acid, dodecanoic acid, glycolic acid, lactic acid, 2- or 3-hydroxybutyric acid, ⁇ -aminobutyric acid (GABA), gluconic acid, glucosemonocarboxylic acid, benzoic acid, salicylic acid, phenylacetic acid and mandelic acid, fumaric acid, succinic acid, adipic acid, pimelic acid, suberic acid, azeiaic acid, maleic acid, tartaric acid, citric acid, glucaric acid, galactaric acid, amino acids (such as glutamic acid
- pharmaceutically acceptable salts include acid salts of inorganic bases, such as salts containing alkaline cations (e.g., Li + , Na + , or K + ), alkaline earth cations (e.g., Mg +2 , Ca +2 , or Ba +2 ), the ammonium cation, as well as acid salts of organic bases, including aliphatic and aromatic substituted ammonium, and quaternary ammonium cations, such as those arising from protonation or peralkylation of triethylamine, NN-diethylamine, NN-dicyclohexylamine, lysine, pyridine, N,N- dimethylaminopyridine (DMAP), l,4-diazabiclo[2.2.2]octane (DABCO), 1,5- diazabicyclo[4.3.0]non-5-ene (DB ⁇ ) and l,8-diazabicyclo[5.4.0]undec
- Base salts include alkali metal salts such as potassium and sodium salts, alkaline earth metal salts such as calcium and magnesium salts, and ammonium salts with organic bases such as dicyclohexylamine and N-methyl-D-glucamine. Additionally, basic nitrogen containing groups may be quaternized with such agents as lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, and dibutyl sulfate; and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and strearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides and others.
- lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides
- prodrugs are well known in the art in order to enhance the properties of the parent compound; such properties include solubility, absorption, biostability and release time (see “Pharmaceutical Dosage Form and Drug Delivery Systems” (Sixth Edition), edited by Ansel et al., published by Williams & Wilkins, pages 27-29, (1995) which is hereby incorporated by reference).
- ⁇ 4-[2-N-methylcarbamoyl-4-pyridyloxy]phenyl ⁇ urea a compound of the present invention, as well as several of its analogs described herein, has been demonstrated in in vitro (biochemical) and in vivo (cellular) assays of PDGFR activity. While not wishing to be bound by any theory or mechanism of action, it has been found that compounds of the present invention possess the ability to modulate PDGFR kinase activity. The methods of the present invention, however, are not limited to any particular mechanism or how the compounds achieve their therapeutic effect.
- modulate it is meant that the functional activity of the pathway (or a component of it) is changed in comparison to its normal activity in the absence of the compound.
- kinase activity it is meant a catalytic activity in which a gamma-phosphate from adenosine triphosphate (ATP) is transferred to an amino acid residue (e.g., serine, threonine, or tyrosine) in a protein substrate.
- ATP adenosine triphosphate
- N compound can modulate kinase activity, e.g., inhibiting it by directly competing with ATP for the ATP-binding pocket of the kinase, by producing a conformational change in the enzyme's structure that affects its activity (e.g., by disrupting the biologically-active three-dimensional structure), etc.
- Kinase activity can be determined routinely using conventional assay methods.
- Kinase assays typically comprise the kinase enzyme, substrates, buffers, and components of a detection system.
- a typical kinase assay involves the reaction of a protein kinase with a peptide substrate and an ATP, such as 32 P-ATP, to produce a phosphorylated end-product (for instance, a phosphoprotein when a peptide substrate is used.
- a phosphorylated end-product for instance, a phosphoprotein when a peptide substrate is used.
- the resulting end-product can be detected using any suitable method.
- radioactive ATP is utilized, a radioactively labeled phosphoprotein can be separated from the unreacted gamma-32P-ATP using an affinity membrane or gel electrophoresis, and then visualized on the gel using autoradiography or detected with a scintillation counter. ⁇ on-radioactive methods can also be used.
- Methods can utilize an antibody that recognizes the phosphorylated substrate, e.g., an anti- phosphotyrosine antibody.
- kinase enzyme can be incubated with a substrate in the presence of ATP and kinase buffer under conditions that are effective for the enzyme to phosphorylate the substrate.
- the reaction mixture can be separated, e.g., electiophoretically, and then phosphorylation of the substrate can be measured, e.g., by Western blotting using an anti-phosphotyrosine antibody.
- the antibody can be labeled with a detectable label, e.g., an enzyme, such as HRP, avidin or biotin, chemiluminescent reagents, etc.
- TR-FRET time-resolved fluorescence resonance energy transfer
- the compounds of the present invention can be used to treat and/or prevent any disease or condition mediated by signal transduction pathways comprising platelet-derived growth factor receptor (PDGFR).
- PDGFR platelet-derived growth factor receptor
- a disease or condition "mediated" by PDGFR indicates that receptor is a part of a signal transduction pathway that is involved in any aspect of the disease phenotype (e.g., where a defect in the receptor itself is involved in "causing” the disease; where stimulation of the receptor by its ligand induces cell tnotility, migration, and/or proliferation that produces a disease phenotype; where receptor stimulation or phosphorylation results in restonosis; any functional activity of PDGFR that, when inappropriately expressed, results in a disease symptom and/or phenotype).
- treating is used conventionally, e.g., the management or care of a subject for the purpose of combating, alleviating, reducing, relieving, improving the condition of, etc., of a disease or disorder.
- Diseases and conditions that can be treated include, but are not limited to the prevention of restenosis and graft rejection.
- the following patents and publication relate to PDGF/PDGFR inhibition and are incorporated herein for their description of the disease states mediated by PDGFR- beta and assays to determine such activity. US 5,094,941 Hart, et al. US 5,371,205 Kelly, et al. US 5,418,135 Pang US 5,444, 151 Nassbotn, et al.
- PDGFR-beta mediated diseases include, e.g., diseases or conditions characterized by cell proliferation, cell matrix production, cell movement, and/or extracellular matrix production.
- diseases or conditions include, e.g., tumors, malignancies, cancer, metastasis, chronic myeloid leukemia, inflammation, renal disease, diabetic nephropathy, mesangial proliferative glomerulonephritis, fibrotic conditions, atherosclerosis, restenosis, hypertension-related arterosclerosis, venous bypass graft arterosclerosis, scleroderma, interstitial pulmonary diseases, synovial disorders, arthritis, leukemias, lymphomas, etc.
- the present invention also relates to devices and other blood and cell contacting materials, such as vascular grafts, cardiac valves, stents, and catheters, which comprise compounds of the present invention.
- Percutaneous transluminal coronary angioplasty PTCA
- PTCA Percutaneous transluminal coronary angioplasty
- PTCA can relieve myocardial ischemia in patients with coronary artery disease by reducing lumen obstruction and improving coronary flow.
- stenosis following PTCA is a significant problem, with about 25% to 35% of the patients developing restenosis within 1 to 3 months. Stents
- the present invention provides an implantable medical device, such as a stent or graft, which comprises one or more compounds of the present invention.
- Stents are scaffoldings, typically cylindrical or tubular in shape, which are inserted into an anatomical channel to physically hold it open, and if desired, to expand the walls of the channel.
- Stents can be crimped on to balloon catheters for insertion through small cavities, positioned in a desired location, and then expanded to a larger diameter. Stents can be either balloon expandable or self-expanding. Grafts are typically placed in a blood vessel to either replace a diseased segment that has been removed, or to form a bypass conduit through a damaged segment of the vessel wall as is the case with an aneurysm, for example.
- the graft has a tubular portion that spans the site of the damaged tissue and through which the blood flows.
- the graft has sections at both ends of the tube that are used to secure the graft to the inside of a vessel wall.
- the graft also has an outer surface, portions of which are in contact with an inner surface of the blood vessel wall, and an inner surface in contact with the blood flowing through the vessel.
- Stents can be of any design or shape that is useful for the desired purpose.
- stents can be balloon expandable, self-expanding, tube, wire, sheet, ribbon, coil, helical spiral, woven, comprising individual rings, comprising sequential rings, closed cell, open cell, spiral articulated slotted tube, sinusoidal pattern, helical fused sinusoidal elements, corrugated ring, Wiktor tantalum stent, etc.
- stents include, Cordis Palmaz-Schatz, Cordis Crown, Bx-Neclocity, S670, S7, ACS Multi-Link, Multi-Link Tetra, Multi-Link Penta, ⁇ IR, and Express. They can be made of any suitable material(s), including, e.g., stainless steel, gold, platinum iridium, polymers, niobium alloy, cobalt alloys, nickel-titanium, cobalt-chromium, etc. Active agents can be coated directly on to an implantable medical device, or impregnated or otherwise associated with a material or carrier (e.g., a polymeric substance) which is then placed in contact with it.
- a material or carrier e.g., a polymeric substance
- the active agent is released, thereby resulting in its delivery to the local tissues.
- These can also be referred to as coated, medicated, or drug-eluting implantable devices.
- Metallic designs can be coated with thin (e.g., 5-10 micrometers) elastomeric biostable polymer surface membrane coatings which comprise the active compound.
- the stent backbone can also comprise drilled holes or wells that comprise the drug (e.g., in a polymeric time-release substrate). Alternatively, it can be present in a film that is cast on the stent backbone. Any method of associating a compound of the present invention with an implantable device can be used.
- Compounds can be embedded, implanted, coated, impregnated, layered, covered, etc. directly on to the device, or otherwise associated with a carrier material.
- implantable devices drug- eluting devices, materials to achieve drug delivery, etc.
- the present invention is not limited by which are utilized. See, e.g., Waksman, Cardiovasc Radiat Med. 2002 Jul-Dec;3(3-4):226-41; Eberhart et al., J Biomater Sci Polym Ed. 2003;14(4):299-312; Wieneke et al., Expert Opin Investig Drugs. 2003 May;12(5):771-9; Tsuji et al., Int J Cardiovasc Intervent.
- the compound can be combined with materials which controllably-release it into the system, e.g., to achieve steady-state concentrations of the compound.
- the devices can further comprise any pharmacological or active agent which is useful for treating and/or preventing restenosis, including, but not limited to, antibiotic, antineoplastic, anti-inflammatory, antiplatelet, anticoagulant, fibrinolytic, thrombin inhibitor, antimitotic, and antiproliferative agents.
- the present invention provides an intravascular stent for introduction into a vascular lumen, comprising, e.g., an elongated body having surfaces, wherein said surfaces comprise an effective amount of a compound of the present invention to prevent and/or treat and/or delay restenosis.
- the stent can have inner and outer surfaces, where one surface or both are coated with compounds.
- the stent can have any structure as mentioned above, e.g., a scaffold or backbone that is expandable, self-expanding, tube, wire, sheet, ribbon, coil, helical spiral, woven, etc.
- the surfaces of the stent can be coated directly with the compound, or associated with a carrier or substrate that comprises the compound, e.g., where the substrate or carrier is impregnated with a compound of formula I.
- the stent can have any suitable geometry, e.g., an elongated body which is substantially cylindrical.
- diaryl ureas of Formula I may be prepared by the use of known chemical reactions and procedures, some from starting materials that are commercially available. Nevertheless, general preparative methods are provided below to aid one skilled in the art in synthesizing these compounds. The following general preparative methods are presented to aid the reader in synthesizing the compounds of the present invention. All variable groups of these methods are as described in the generic description if they are not specifically defined below. It is recognized that compounds of the invention with each claimed optional functional group cannot be prepared with each of the below-listed methods. Within the scope of each method optional substituents are used which are stable to the reaction conditions, or the functional groups which may participate in the reactions are present in protected form where necessary, and the removal of such protective groups is completed at appropriate stages by methods well known to those skilled in the art.
- the urea compounds (I) can be synthesized as above by reacting amino compounds (III) with isocyanate compounds (II).
- the compounds (II) are commercially available or can be synthesized according to methods commonly known to those skilled in the art [e.g. from treatment of an amine with phosgene or a phosgene equivalent such as trichloromethyl chloroformate (diphosgene), bis(trichloromethyl)carbonate (triphosgene), or N,N'- carbonyldiimidazole (CDI); or, alternatively by a Curtius-type rearrangement of an amide, or a carboxylic acid derivative, such as an ester, an acid halide or an anhydride].
- phosgene or a phosgene equivalent such as trichloromethyl chloroformate (diphosgene), bis(trichloromethyl)carbonate (triphosgene), or N,N'- carbonyldiimidazole (
- the compounds (III) can be synthesized according methods commonly known to those skilled in the art.
- specific preparations of diaryl ureas of Formula (I) are already described in the patent literature, and can be adapted to the compounds of the present invention.
- Miller S. et al "Inhibition of p38 Kinase using Symmetrical and Unsymmetrical Diphenyl Ureas" PCT Int. Appl WO 99 32463
- Miller, S et al. “Inhibition of raf Kinase using Symmetrical and Unsymmetrical Substituted Diphenyl Ureas” PCT Int. Appl., WO 99 32436
- Dumas, J. et al. "Inhibition of p38 Kinase Activity using Substituted Heterocyclic Ureas” PCT Lit. Appl, WO 99 32111
- Suitable solvents comprise the customary organic solvents which are inert under the reaction conditions.
- Non-limiting examples include ethers such as diethyl ether, dioxane, tetrahydrofuran, 1,2-dimethoxy ethane; hydrocarbons such as benzene, toluene, xylene, hexane, cyclohexane, mineral oil fractions; halogenated hydrocarbons such as dichloromethane, trichloromethane, carbon tetrachloride, dichloroethane, trichloroethylene, chlorobenzene; alcohols such as methanol, ethanol, n-propanol, isopropanol; esters such as ethyl acetate; ketones such as acetone; nitriles such as acetonitrile; heteroaromatics such as pyridine; polar solvents such as dimethyl formamide and hexamethyl phosphoric acid tris-amide
- the compounds (III) are generally employed in an amount of from 1 to 3 mol per mol of compounds (II); an equimolar amount or slight excess of compounds (III) is preferred.
- the reaction of the compounds (II) with (III) is generally carried out within a relatively wide temperature range. In general, they are carried out in a range of from -20 to 200°C, preferably from 0 to 100°C, and more preferably from 25 to 50°C.
- the steps of this reaction are generally carried out under atmospheric pressure. However, it is also possible to carry them out under superatmospheric pressure or under reduced pressure (for example, in a range of from 0.5 to 5 bar).
- the reaction time can generally be varied within a relatively wide range. In general, the reaction is finished after a period of from 2 to 24 hours, preferably from 6 to 12 hours.
- Synthetic transformations that may be employed in the synthesis of compounds of Formula I and in the synthesis of intermediates involved in the synthesis of compounds of Formula I are known by or accessible to one skilled in the art. Collections of synthetic transformations may be found in compilations, such as: • J. March. Advanced Organic Chemistry, 4th ed.; John Wiley: New York (1992) • R.C. Larock. Comprehensive Organic Transformations, 2nd ed.; Wiley- VCH: New York (1999)
- the compounds may be administered orally, topically, parenterally, by inhalation or spray or rectally in dosage unit formulations.
- administration by injection' includes intravenous, intramuscular, subcutaneous and parenteral injections, as well as use of infusion techniques.
- One or more compounds may be present in association with one or more non-toxic pharmaceutically acceptable carriers and if desired other active ingredients.
- Compositions intended for oral use may be prepared according to any suitable method known to the art for the manufacture of pharmaceutical compositions. Such compositions may contain one or more agents selected from the group consisting of diluents, sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide palatable preparations.
- Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients that are suitable for the manufacture of tablets.
- excipients may be, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; and binding agents, for example magnesium stearate, stearic acid or talc.
- the tablets may be uncoated or they may be coated by known techniques to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
- a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. These compounds may also be prepared in solid, rapidly released form.
- Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil.
- Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions.
- excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally occurring phosphatide, for example, lecithin, or condensation products or an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethylene oxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate.
- dispersing or wetting agents may be a naturally occurring phosphatide, for example, lecithin, or condensation products or an alky
- the aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propylp-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.
- Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example, sweetening, flavoring and coloring agents, may also be present.
- the compounds may also be in the form of non-aqueous liquid formulations, e.g., oily suspensions which may be formulated by suspending the active ingredients in a vegetable oil, for example arachis oil, olive oil, sesame oil or peanut oil, or in a mineral oil such as liquid paraffin.
- the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide palatable oral preparations. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
- Pharmaceutical compositions of the invention may also be in the form of oil- in-water emulsions.
- the oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these.
- Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate.
- the emulsions may also contain sweetening and flavoring agents.
- Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
- the compounds may also be administered in the form of suppositories for rectal administration of the drug.
- These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
- suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
- Such materials include cocoa butter and polyethylene glycols.
- the compounds of this invention may also be administered parenterally, that is, subcutaneously, intravenously, intraocularly, intrasynovially, intramuscularly, or interperitoneally, as injectable dosages of the compound in a physiologically acceptable diluent with a pharmaceutical carrier which can be a sterile liquid or mixture of liquids such as water, saline, aqueous dextrose and related sugar solutions, an alcohol such as ethanol, isopropanol, or hexadecyl alcohol, glycols such as propylene glycol or polyethylene glycol, glycerol ketals such as 2,2-dimethyl-l,l- dioxolane-4-methanol, ethers such as poly(ethylene glycol) 400, an oil, a fatty acid, a fatty acid ester or, a fatty acid glyceride, or an acetylated fatty acid glyceride, with or without the addition of a pharmaceutically acceptable surfactant such as
- Suitable fatty acids include oleic acid, stearic acid, isostearic acid and myristic acid.
- Suitable fatty acid esters are, for example, ethyl oleate and isopropyl myristate.
- Suitable soaps include fatty acid alkali metal, ammonium, and triethanolamine salts and suitable detergents include cationic detergents, for example dimethyl dialkyl ammonium halides, alkyl pyridinium halides, and alkylamine acetates; anionic detergents, for example, alkyl, aryl, and olefin sulfonates, alkyl, olefin, ether, and monoglyceride sulfates, and sulfosuccinates; non-ionic detergents, for example, fatty amine oxides, fatty acid alkanolamides, and poIy(oxyethylene- oxypropylene)s or ethylene oxide or propylene oxide copolymers; and amphoteric detergents, for example, alkyl beta-aminopropionates, and 2-alkylimidazoline quarternary ammonium salts, as well as mixtures.
- suitable detergents include cationic detergents, for example di
- compositions of this invention will typically contain from about 0.5%) to about 25% by weight of the active ingredient in solution. Preservatives and buffers may also be used advantageously. In order to minimize or eliminate irritation at the site of injection, such compositions may contain a non-ionic surfactant having a hydrophile-lipophile balance (HLB) of from about 12 to about 17. The quantity of surfactant in such formulation ranges from about 5% to about 15% by weight.
- the surfactant can be a single component having the above HLB or can be a mixture of two or more components having the desired HLB.
- surfactants used in parenteral formulations are the class of polyethylene sorbitan fatty acid esters, for example, sorbitan monooleate and the high molecular weight adducts of ethylene oxide with a hydrophobic base, formed by the condensation of propylene oxide with propylene glycol.
- the pharmaceutical compositions may be in the form of sterile injectable aqueous suspensions.
- Such suspensions may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents such as, for example, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvmylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents which may be a naturally occurring phosphatide such as lecithin, a condensation product of an alkylene oxide with a fatty acid, for example, polyoxyethylene stearate, a condensation product of ethylene oxide with a long chain aliphatic alcohol, for example, heptadeca-ethyleneoxycetanol, a condensation product of ethylene oxide with a partial ester derived form a fatty acid and a hexitol such as polyoxyethylene sorbitol monooleate, or a condensation product of an ethylene oxide with a partial ester derived from a fatty acid and a hexitol anhydride, for example polyoxyethylene sorb
- the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent.
- Diluents and solvents that may be employed are, for example, water, Ringer's solution, isotonic sodium chloride solutions and isotonic glucose solutions.
- sterile fixed oils are conventionally employed as solvents or suspending media.
- any bland, fixed oil may be employed including synthetic mono- or diglycerides.
- fatty acids such as oleic acid can be used in the preparation of injectables.
- transdermal patches may be used to provide continuous or discontinuous infusion of the compounds of the present invention in controlled amounts.
- the construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art (see, e.g., US Patent 5,023,252, issued June 11, 1991, incorporated herein by reference). Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.
- a solution or suspension of a compound of Formula I in a suitable volatile solvent optionally containing penetration enhancing agents can be combined with additional additives known to those skilled in the art, such as matrix materials and bacteriocides. After sterilization, the resulting mixture can be formulated following known procedures into dosage forms.
- additional additives known to those skilled in the art, such as matrix materials and bacteriocides.
- the resulting mixture can be formulated following known procedures into dosage forms.
- a solution or suspension of a compound of Formula I may be formulated into a lotion or salve.
- Suitable solvents for processing transdermal delivery systems include lower alcohols such as ethanol or isopropyl alcohol, lower ketones such as acetone, lower carboxylic acid esters such as ethyl acetate, polar ethers such as tetiahydrofuran, lower hydrocarbons such as hexane, cyclohexane or benzene, or halogenated hydrocarbons such as dichloromethane, chloroform, trichlorotrifluoroethane, or trichlorofluoroethane.
- lower alcohols such as ethanol or isopropyl alcohol
- lower ketones such as acetone
- lower carboxylic acid esters such as ethyl acetate
- polar ethers such as tetiahydrofuran
- lower hydrocarbons such as hexane, cyclohexane or benzene
- halogenated hydrocarbons such as dichloromethane, chloroform,
- Suitable solvents may also include mixtures of one or more materials selected from lower alcohols, lower ketones, lower carboxylic acid esters, polar ethers, lower hydrocarbons, halogenated hydrocarbons.
- Suitable penetration enhancing materials for transdermal delivery system are known to those skilled in the art, and include, for example, monohydroxy or polyhydroxy alcohols such as ethanol, propylene glycol or benzyl alcohol, saturated or unsaturated C 8 -C ⁇ 8 fatty alcohols such as lauryl alcohol or cetyl alcohol, saturated or unsaturated C 8 -C 18 fatty acids such as stearic acid, saturated or unsaturated fatty esters with up to 24 carbons such as methyl, ethyl, propyl, isopropyl, n-butyl, sec- butyl isobutyl tert-butyl or monoglycerin esters of acetic acid, capronic acid, lauric acid, myristinic acid, stearic acid, or palmitic acid
- Additional penetration enhancing materials include phosphatidyl derivatives such as lecithin or cephalin, terpenes, amides, ketones, ureas and their derivatives, and ethers such as dimethyl isosorbid and diethyleneglycol monoethyl ether.
- Suitable penetration enhancing formulations may also include mixtures of one or more materials selected from monohydroxy or polyhydroxy alcohols, saturated or unsaturated C 8 -C 18 fatty alcohols, saturated or unsaturated C 8 -C ⁇ 8 fatty acids, saturated or unsaturated fatty esters with up to 24 carbons, diesters of saturated or unsaturated discarboxylic acids with a total of up to 24 carbons, phosphatidyl derivatives, terpenes, amides, ketones, ureas and their derivatives, and ethers.
- Suitable binding materials for transdermal delivery systems are known to those skilled in the art and include polyacrylates, silicones, polyurethanes, block polymers, styrenebutadiene copolymers, and natural and synthetic rubbers. Cellulose ethers, derivatized polyethylenes, and silicates may also be used as matrix components. Additional additives, such as viscous resins or oils may be added to increase the viscosity of the matrix. Controlled release formulations for parenteral administration include liposomal, polymeric microsphere and polymeric gel formulations, which are known in the art. It may be desirable or necessary to introduce the pharmaceutical composition to the patient via a mechanical delivery device. The construction and use of mechanical delivery devices for the delivery of pharmaceutical agents is well known in the art.
- compositions of the invention can also contain other conventional pharmaceutically acceptable compounding ingredients, generally referred to as carriers or diluents, as necessary or desired. Conventional procedures for preparing such compositions in appropriate dosage forms can be utilized. Such ingredients and procedures include those described in the following references, each of which is incorporated herein by reference: Powell, M.F. et al, "Compendium of Excipients for Parenteral Formulations " PDA J. Pharmaceut. Sci. Tech. 1998, 52(5), 238-311;
- This invention also relates to administering pharmaceutical compositions containing one or more compounds of the present invention. These compositions can be utilized to achieve the desired pharmacological effect by administration to a patient in need thereof.
- a patient for the purpose of this invention, is a mammal, including a human, in need of treatment for the particular condition or disease.
- the present invention includes pharmaceutical compositions which are comprised of a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound, or salt thereof, of the present invention.
- a pharmaceutically acceptable carrier is any carrier which is relatively non-toxic and innocuous to a patient at concentrations consistent with effective activity of the active ingredient so that any side effects ascribable to the carrier do not vitiate the beneficial effects of the active ingredient.
- a pharmaceutically effective amount of compound is that amount which produces a result or exerts an influence on the particular condition being treated.
- the compounds of the present invention can be administered with pharmaceutically- acceptable carriers well known in the art using any effective conventional dosage unit forms, including immediate, slow and timed release preparations, orally, parenterally, topically, nasally, ophthalmically, otically, sublingually, rectally, vaginally, and the like.
- the compounds can be formulated into solid or liquid preparations such as capsules, pills, tablets, troches, lozenges, melts, powders, solutions, suspensions, or emulsions, and may be prepared according to methods known to the art for the manufacture of pharmaceutical compositions.
- the solid unit dosage forms can be a capsule which can be of the ordinary hard- or soft-shelled gelatin type containing, for example, surfactants, lubricants, and inert fillers such as lactose, sucrose, calcium phosphate, and corn starch.
- the compounds of this invention may be tableted with conventional tablet bases such as lactose, sucrose and cornstarch in combination with binders such as acacia, com starch or gelatin, disintegrating agents intended to assist the break-up and dissolution of the tablet following administration such as potato starch, alginic acid, corn starch, and guar gum, gum tragacanth, acacia, lubricants intended to improve the flow of tablet granulation and to prevent the adhesion of tablet material to the surfaces of the tablet dies and punches, for example talc, stearic acid, or magnesium, calcium or zinc stearate, dyes, coloring agents, and flavoring agents such as peppermint, oil of wintergreen, or cherry flavoring, intended to enhance the aesthetic qualities of the tablets and make them more acceptable to the patient.
- binders such as acacia, com starch or gelatin
- disintegrating agents intended to assist the break-up and dissolution of the tablet following administration such as potato starch, alginic acid,
- Suitable excipients for use in oral liquid dosage forms include dicalcium phosphate and diluents such as water and alcohols, for example, ethanol, benzyl alcohol, and polyethylene alcohols, either with or without the addition of a pharmaceutically acceptable surfactant, suspending agent or emulsifying agent.
- Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance tablets, pills or capsules may be coated with shellac, sugar or both.
- Commonly used pharmaceutical ingredients which can be used as appropriate to formulate the composition for its intended route of administration include: acidifying agents (examples include but are not limited to acetic acid, citric acid, fumaric acid, hydrochloric acid, nitric acid); alkalinizing agents (examples include but are not limited to ammonia solution, ammonium carbonate, diethanolamine, monoethanolamine, potassium hydroxide, sodium borate, sodium carbonate, sodium hydroxide, triethanolamine, trolamine); adsorbents (examples include but are not limited to powdered cellulose and activated charcoal); aerosol propellants (examples include but are not limited to carbon dioxide, CC1 2 F 2 , F 2 C1C-CC1F 2 and CC1F 3 ) air displacement agents (examples include but are not limited to nitrogen and argon); antifungal preservatives (examples include but are not limited to benzoic acid, butylparaben, ethylparab
- clarifying agents include but are not limited to bentonite
- emulsifying agents include but are not limited to acacia, cetomacrogol, cetyl alcohol, glyceryl monostearate, lecithin, sorbitan monooleate, polyoxyethylene 50 monostearate
- encapsulating agents include but are not limited to gelatin and cellulose acetate phthalate
- flavorants include but are not limited to anise oil, cinnamon oil, cocoa, menthol, orange oil, peppermint oil and vanillin
- humectants include but are not limited to glycerol, propylene glycol and sorbitol
- levigating agents include but are not
- the total amount of the active ingredient to be administered will generally range from about 0.001 mg/kg to about 200 mg/kg, and preferably from about 0.01 mg/kg to about 20 mg/kg body weight per day.
- a unit dosage may contain from about 0.5 mg to about 1500 mg of active ingredient, and can be administered one or more times per day.
- the daily oral dosage regimen will preferably be from 0.01 to 200 mg/Kg of total body weight.
- the daily dosage for administration by injection, including intravenous, intramuscular, subcutaneous and parenteral injections, and use of infusion techniques will preferably be from 0.01 to 200 mg/Kg of total body weight.
- the daily rectal dosage regime will preferably be from 0.01 to 200 mg/Kg of total body weight.
- the daily vaginal dosage regime will preferably be from 0.01 to 200 mg/Kg of total body weight.
- the daily topical dosage regime will preferably be from
- transdermal concentration will preferably be that required to maintain a daily dose of from 0.01 to
- the daily inhalation dosage regime will preferably be from 0.01 to 100 mg/Kg of total body weight. These dosages regimes can be achieved with multiple dosages within a single day or extended dosages, such as those given on a weekly or monthly basis. Based upon standard laboratory techniques known to evaluate compounds, by standard toxicity tests and by standard pharmacological assays for the determination of treatment of the conditions identified above in mammals, and by comparison of these results with the results of known medicaments that are used to treat these conditions, the effective dosage of the compounds of this invention can readily be determined for treatment of each desired indication.
- the amount of the active ingredient to be administered in the treatment of one of these conditions can vary widely according to such considerations as the particular compound and dosage unit employed, the mode of administration, the period of treatment, the age and gender of the patient treated, and the nature and extent of the condition treated. It will be appreciated by those skilled in the art that the particular method of administration will depend on a variety of factors, all of which are considered routinely when administering therapeutics. It will also be appreciated by one skilled in the art that the specific dose level for a given patient depends on a variety of factors, including specific activity of the compound administered, age, body weight, health, sex, diet, time and route of administration, rate of excretion, etc.
- the optimal course of treatment i.e., the mode of treatment and the daily number of doses of a compound of Formula I or a pharmaceutically acceptable salt thereof given for a defined number of days
- the specific dose level for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, and rate of excretion, drug combination and the severity of the condition undergoing therapy.
- the optimal course of treatment i.e., the mode of treatment and the daily number of doses of a compound of this invention given for a defined number of days
- Dosages and compound efficacy can also be determined routinely using in vitro and in vivo animal models.
- murine models have been developed using mice deficent in apolipoprotein E (Leidenfrost et al., Am. J. Pathol., 163:773- 778, 2003). See, also Bayes-Genis et al, Curr. Intv. Cardio. Rep., 2:303-308, 200, for reviews of rat, rabbit, canine, baboon, and procine models.
- Pharmaceutical compositions according to the present invention can be illustrated as follows:
- Sterile IV Solution A 5 mg/ml solution of the desired compound of this invention is made using sterile, injectable water, and the pH is adjusted if necessary. The solution is diluted for administration to 1 - 2 mg/ml with sterile 5% dextrose and is administered as an IV infusion over 60 minutes.
- a sterile preparation can be prepared with (i) 100 - 1000 mg of the desired compound of this invention as a lyophilized powder, (ii) 32- 327 mg/ml sodium citrate, and (iii) 300 - 3000 mg Dextran 40.
- the formulation is reconstituted with sterile, injectable saline or dextrose 5% to a concentration of 10 to 20 mg/ml, which is further diluted with saline or dextrose 5% to 0.2 - 0.4 mg/ml, and is administered either IV bolus or by IV infusion over 15 - 60 minutes.
- Intramuscular suspension The following solution or suspension can be prepared, for intramuscular injection: 50 mg/ml of the desired, water-insoluble compound of this invention 5 mg/ml sodium carboxymethylcellulose 4 mg/ml TWEEN 80 9 mg/ml sodium chloride 9 mg/ml benzyl alcohol Hard Shell Capsules; A large number of unit capsules are prepared by filling standard two-piece hard galantine capsules each with 100 mg of powdered active ingredient, 150 mg of lactose, 50 mg of cellulose and 6 mg of magnesium stearate.
- Soft Gelatin Capsules A mixture of active ingredient in a digestible oil such as soybean oil, cottonseed oil or olive oil is prepared and injected by means of a positive displacement pump into molten gelatin to form soft gelatin capsules containing 100 mg of the active ingredient. The capsules are washed and dried. The active ingredient can be dissolved in a mixture of polyethylene glycol, glycerin and sorbitol to prepare a water miscible medicine mix.
- Tablets A large number of tablets are prepared by conventional procedures so that the dosage unit was 100 mg of active ingredient, 0.2 mg. of colloidal silicon dioxide, 5 mg of magnesium stearate, 275 mg of microcrystalline cellulose, 11 mg. of starch, and 98.8 mg of lactose. Appropriate aqueous and non-aqueous coatings may be applied to increase palatability, improve elegance and stability or delay absorption. Immediate Release Tablets/Capsules: These are solid oral dosage forms made by conventional and novel processes. These units are taken orally without water for immediate dissolution and delivery of the medication. The active ingredient is mixed in a liquid containing ingredient such as sugar, gelatin, pectin and sweeteners.
- Murine PDGFR FRET biochemical assay This assay was formatted in a 96-well black plate (Costar 3915). The following reagents (and their sources) are used: Europium-labeled anti- phosphotyrosine antibody pY20 and streptavidin-APC; poly GT-biotin, and mouse PDGFR within DRT.
- reaction conditions are as follows: 1 nM mouse PDGFR is combined with 20 ⁇ M ATP, 7nM poly GT-biotin, 1 nM pY20 antibody, 5 nM streptavidin-APC, and 1% DMSO in assay buffer (50 mM HEPES pH 7.5, 10 mM MgCl 2 , 0.1 mM EDTN 0.015% BRIJ 35, 0.1 mg/mL BSN 0.1% mercaptoethanol). Reaction is initiated upon addition of enzyme. Final reaction volume in each well is 100 ⁇ L. After 90 minutes, the reaction is stopped by addition of 10 ⁇ L/well of 5 ⁇ M staurosporine.
- the following compounds show an IC 50 of less than 10 micromolar in this biochemical assay, which represents a marked inhibition of PDGFR: ⁇ -(4-chloro-3-(trifluoromethyl)phenyl)- ⁇ '-(4-(2-(N-methylcarbamoyl)-4-pyridyl oxy)phenyl) urea,
- pPDGFR-beta sandwich ELISA in AoSMC cells 100K P3-P6 Aortic SMC were plated in each well of 12-well cluster in 1000 uL volume/ well of SGM-2 using standard cell culture techniques. Next day, cells were rinsed with 1000 uL D-PBS (Gibco) once, then serum starved in 500 uL SBM (smooth muscle cell basal media) with 0.1% BSA (Sigma, Cat A9576) overnight. Compounds were diluted at a dose range from (10 uM to 1 nM in 10-fold dilution steps in DMSO. Final DMSO concentration 0.1%).
- Lysates are put in eppendorf tubes to which 15 uL of agarose-conjugated anti-PDGFR-b antibody is added (Santa Cruz, sc-339) and incubated at 4 °C overnight. Next day, beads are rinsed in 50-volumes of PBS three times and boiled in lx LDS sample buffer (Invitrogen) for 5 minutes. Samples were mn on 3-8% gradient Tris-Acetate gels (Invitrogen) and transferred onto Nitrocellulose. Membranes were blocked in 1%> BSA TBS-T for 1 hr. before incubation in anti-phospho-PDGFR-b (Tyr-857) antibody in blocking buffer (1 : 1000 dilution) for 1 hour. After three washes in TBS-T, membranes were incubated in Goat anti-rabbit HRP IgG (Amersham, 1 :25000 dilution) for 1 hr. Three more washes followed before addition of ECL substrate.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2526636A CA2526636C (en) | 2003-05-20 | 2004-05-19 | Diaryl ureas for diseases mediated by pdgfr |
DE602004007382T DE602004007382T2 (en) | 2003-05-20 | 2004-05-19 | DIARYL UREAS FOR PDGFR MEDIATED DISEASES |
EP04776037A EP1626714B1 (en) | 2003-05-20 | 2004-05-19 | Diaryl ureas for diseases mediated by pdgfr |
PL04776037T PL1626714T3 (en) | 2003-05-20 | 2004-05-19 | Diaryl ureas for diseases mediated by pdgfr |
DK04776037T DK1626714T3 (en) | 2003-05-20 | 2004-05-19 | Dirarylurine drugs for diseases mediated by PDGFR |
JP2006533210A JP4860474B2 (en) | 2003-05-20 | 2004-05-19 | Diarylureas for diseases mediated by PDGFR |
MXPA05012486A MXPA05012486A (en) | 2003-05-20 | 2004-05-19 | Diaryl ureas for diseases mediated by pdgfr. |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47173503P | 2003-05-20 | 2003-05-20 | |
US60/471,735 | 2003-05-20 | ||
US52039903P | 2003-11-17 | 2003-11-17 | |
US60/520,399 | 2003-11-17 | ||
US55606204P | 2004-03-25 | 2004-03-25 | |
US60/556,062 | 2004-03-25 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005000284A2 true WO2005000284A2 (en) | 2005-01-06 |
WO2005000284A3 WO2005000284A3 (en) | 2005-03-10 |
Family
ID=33545309
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/015655 WO2004113274A2 (en) | 2003-05-20 | 2004-05-19 | Diaryl ureas with kinase inhibiting activity |
PCT/US2004/015653 WO2005000284A2 (en) | 2003-05-20 | 2004-05-19 | Diaryl ureas for diseases mediated by pdgfr |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/015655 WO2004113274A2 (en) | 2003-05-20 | 2004-05-19 | Diaryl ureas with kinase inhibiting activity |
Country Status (12)
Country | Link |
---|---|
US (2) | US20070020704A1 (en) |
EP (2) | EP1626714B1 (en) |
JP (2) | JP4860474B2 (en) |
AT (2) | ATE366108T1 (en) |
CA (2) | CA2526617C (en) |
DE (2) | DE602004011340T2 (en) |
DK (2) | DK1626714T3 (en) |
ES (2) | ES2288694T3 (en) |
MX (1) | MXPA05012486A (en) |
PL (2) | PL1636585T3 (en) |
PT (2) | PT1636585E (en) |
WO (2) | WO2004113274A2 (en) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006034796A1 (en) * | 2004-09-29 | 2006-04-06 | Bayer Healthcare Ag | Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-n-methylpyridine-2-carboxamide |
JP2009514910A (en) * | 2005-11-10 | 2009-04-09 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | Diarylureas for treating pulmonary hypertension |
JP2009514909A (en) * | 2005-11-10 | 2009-04-09 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | Diarylureas for treating pulmonary hypertension |
US7838541B2 (en) | 2002-02-11 | 2010-11-23 | Bayer Healthcare, Llc | Aryl ureas with angiogenesis inhibiting activity |
US7897623B2 (en) | 1999-01-13 | 2011-03-01 | Bayer Healthcare Llc | ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors |
EP2338488A1 (en) | 2006-05-26 | 2011-06-29 | Bayer HealthCare, LLC | Drug combinations with substituted diaryl ureas for the treatment of cancer |
WO2012012404A1 (en) | 2010-07-19 | 2012-01-26 | Bayer Healthcare Llc | Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
US8110587B2 (en) | 2002-02-11 | 2012-02-07 | Bayer Healthcare Llc | Aryl ureas as kinase inhibitors |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
WO2013000909A1 (en) | 2011-06-28 | 2013-01-03 | Bayer Intellectual Property Gmbh | Topical ophthalmological pharmaceutical composition containing sorafenib |
WO2013171318A1 (en) * | 2012-05-18 | 2013-11-21 | Sanofi | Benzo[1,3]dioxine derivatives and their use as lpar5 antagonists |
US8637553B2 (en) | 2003-07-23 | 2014-01-28 | Bayer Healthcare Llc | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
US8653304B2 (en) | 2009-09-30 | 2014-02-18 | Toray Industries, Inc. | 2,3-dihydro-1H-indene-2-yl urea derivative and pharmaceutical application of same |
US8796250B2 (en) | 2003-05-20 | 2014-08-05 | Bayer Healthcare Llc | Diaryl ureas for diseases mediated by PDGFR |
US8877933B2 (en) | 2004-09-29 | 2014-11-04 | Bayer Intellectual Property Gmbh | Thermodynamically stable form of a tosylate salt |
US9737488B2 (en) | 2005-03-07 | 2017-08-22 | Bayer Healthcare Llc | Pharmaceutical composition for the treatment of cancer |
WO2017151044A1 (en) | 2016-03-02 | 2017-09-08 | Medivir Ab | Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine |
US9957232B2 (en) | 2006-10-11 | 2018-05-01 | Bayer Healthcare Llc | 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate |
US10662195B2 (en) | 2009-09-16 | 2020-05-26 | Celgene Car Llc | Protein kinase conjugates and inhibitors |
IT202000022636A1 (en) | 2020-09-25 | 2022-03-25 | Ente Ospedaliero Specializzato In Gastroenterologia Istituto Nazionale Di Ricovero E Cura A Caratter | “COMBINATION THERAPY OF SORAFENIB AND/OR REGORAFENIB WITH THE RECOMBINANT HUMAN PROTEOGLYCAN-4 PROTEIN FOR THE TREATMENT OF HEPATOCARCINOMA” |
US11542492B2 (en) | 2009-12-30 | 2023-01-03 | Celgene Car Llc | Ligand-directed covalent modification of protein |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7371763B2 (en) * | 2001-04-20 | 2008-05-13 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
ES2393900T3 (en) * | 2001-12-03 | 2012-12-28 | Bayer Healthcare Llc | Aryl urea compounds in combination with other cytostatic or cytotoxic agents for the treatment of human cancers |
US20080108672A1 (en) * | 2002-01-11 | 2008-05-08 | Bernd Riedl | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors |
JP4613157B2 (en) * | 2003-01-14 | 2011-01-12 | サイトキネティクス・インコーポレーテッド | Compounds, compositions and methods |
NZ626589A (en) * | 2003-02-21 | 2016-01-29 | Resmed Ltd | Nasal assembly |
US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
KR20060110307A (en) * | 2003-11-28 | 2006-10-24 | 노파르티스 아게 | Diaryl urea derivatives in the treatment of protein kinase dependent diseases |
US7803178B2 (en) * | 2004-01-30 | 2010-09-28 | Trivascular, Inc. | Inflatable porous implants and methods for drug delivery |
PL1765327T3 (en) | 2004-06-17 | 2015-01-30 | Cytokinetics Inc | Compounds, compositions and methods |
GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
US7538223B2 (en) * | 2005-08-04 | 2009-05-26 | Cytokinetics, Inc. | Compounds, compositions and methods |
ATE493652T1 (en) * | 2005-08-11 | 2011-01-15 | Siemens Healthcare Diagnostics | QUANTITATIVE ASSAY FOR PDGFR BETA IN BODY FLUID |
US8329408B2 (en) * | 2005-10-31 | 2012-12-11 | Bayer Healthcare Llc | Methods for prognosis and monitoring cancer therapy |
CA2627873A1 (en) * | 2005-10-31 | 2007-05-10 | Scott Wilhelm | Treatment of cancer with sorafenib |
JP2009513707A (en) | 2005-10-31 | 2009-04-02 | バイエル ヘルスケア リミティド ライアビリティ カンパニー | Diaryl urea and concomitant drugs |
EP1948172A1 (en) * | 2005-11-10 | 2008-07-30 | Bayer HealthCare AG | Diaryl ureas for treating diabetic neuropathy |
WO2007064872A2 (en) * | 2005-12-01 | 2007-06-07 | Bayer Healthcare Llc | Urea compounds useful in the treatment of cancer |
WO2007070683A2 (en) * | 2005-12-15 | 2007-06-21 | Cytokinetics, Inc. | Certain chemical entities, compositions and methods |
US20070208000A1 (en) * | 2005-12-15 | 2007-09-06 | Morgan Bradley P | Certain chemical entities, compositions and methods |
WO2007068380A1 (en) * | 2005-12-15 | 2007-06-21 | Bayer Healthcare Ag | Diaryl urea for treating virus infections |
EP1959947A2 (en) * | 2005-12-15 | 2008-08-27 | Cytokinetics, Inc. | Certain chemical entities, compositions and methods |
JP2009524585A (en) * | 2005-12-15 | 2009-07-02 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | Diarylureas for treating viral infections |
US7825120B2 (en) * | 2005-12-15 | 2010-11-02 | Cytokinetics, Inc. | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas |
EP1959962A2 (en) * | 2005-12-16 | 2008-08-27 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
US7989455B2 (en) * | 2005-12-19 | 2011-08-02 | Cytokinetics, Inc. | Compounds, compositions and methods |
JP5331485B2 (en) * | 2005-12-21 | 2013-10-30 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Substituted pyrimidine derivatives useful for the treatment of cancer and other disorders |
WO2008044688A1 (en) * | 2006-10-11 | 2008-04-17 | Daiichi Sankyo Company, Limited | Urea derivative |
US8680124B2 (en) | 2007-01-19 | 2014-03-25 | Bayer Healthcare Llc | Treatment of cancers with acquired resistance to kit inhibitors |
CA2680398A1 (en) * | 2007-03-20 | 2008-09-25 | Curis, Inc. | Raf kinase inhibitors containing a zinc binding moiety |
EP1992344A1 (en) * | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation |
US7674406B2 (en) * | 2007-06-14 | 2010-03-09 | Bindra Perminder S | Chemiluminescent compositions and methods of making and using thereof |
CN101220024A (en) * | 2007-12-11 | 2008-07-16 | 杜晓敏 | A set of anti-cancer compound restraining kinase |
BRPI0914636A2 (en) * | 2008-06-25 | 2015-10-20 | Bayer Schering Pharma Ag | diary ureas to treat heart failure |
US20110178137A1 (en) * | 2008-06-25 | 2011-07-21 | Bayer Schering Pharma Aktiengesellschaft | Diaryl urea for treating heart failure |
BRPI0918970A2 (en) * | 2008-09-05 | 2019-09-24 | Avila Therapeutics Inc | algorithm for irreversible inhibitor design |
CN103254126A (en) * | 2008-09-19 | 2013-08-21 | 苏州泽璟生物制药有限公司 | Deuterated omega-diphenyl carbamide as well as derivative and pharmaceutical composition including compounds |
CN101362717B (en) * | 2008-09-28 | 2013-02-06 | 四川大学 | 4-(4-amidoanilino)-2-(methylcarbamoyl) pyridine, derivates thereof and preparation, application thereof |
FR2943670B1 (en) * | 2009-03-24 | 2011-05-06 | Sanofi Aventis | ANTICANCER DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
US7964119B2 (en) * | 2009-05-12 | 2011-06-21 | Mega Glow, LLC. | Chemiluminescent powders and methods of making and using thereof |
US8658066B2 (en) | 2009-05-12 | 2014-02-25 | Mega Glow, Llc | Chemiluminescent powders and methods of making and using thereof |
CN102459180B (en) * | 2009-06-09 | 2014-05-14 | 江苏迈度药物研发有限公司 | Urea derivatives as kinase inhibitors |
WO2011028995A1 (en) * | 2009-09-03 | 2011-03-10 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
WO2011092663A2 (en) | 2010-01-29 | 2011-08-04 | Ranbaxy Laboratories Limited | 4-(4-{3-[4-chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-n2-methylpyridine-2-carboxamide dimethyl sulphoxide solvate |
AR081060A1 (en) | 2010-04-15 | 2012-06-06 | Bayer Schering Pharma Ag | PROCEDURE TO PREPARE 4- {4 - [({[4-CHLORINE-3- (TRIFLUOROMETIL) PHENYL] AMINO} CARBONYL) AMINO] -3-FLUOROPHENOXY} -N-METHYLPIRIDIN-2-CARBOXAMIDE |
CN101830847B (en) * | 2010-05-18 | 2012-10-10 | 张南 | Anticancer compound and preparation method thereof |
AP2013006834A0 (en) * | 2010-10-01 | 2013-04-30 | Bayer Ip Gmbh | Substituted N-(2-arylamino)aryl sulfonamide-containing combinations |
WO2014040242A1 (en) * | 2012-09-12 | 2014-03-20 | 湖南有色凯铂生物药业有限公司 | 3-chloro- and 3-methoxy-n-methyl-2-pyridine carboxamide compound and application thereof as anticancer medicament |
EP2976081B1 (en) * | 2013-03-15 | 2020-06-17 | Alumend, LLC | Methods of acute restoration of vascular compliance |
US10519113B2 (en) | 2016-08-17 | 2019-12-31 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds, compositions, and methods of treating cancer |
CN108314703B (en) | 2017-01-17 | 2022-02-01 | 亚飞(上海)生物医药科技有限公司 | Preparation and application of molecular site-specific targeting and activating kinase inhibitor |
SG11201909570PA (en) * | 2017-04-20 | 2019-11-28 | Univ California | K-ras modulators |
CN109771407B (en) * | 2019-03-29 | 2021-11-26 | 成都医学院 | Application of rosmarinic acid in preparation of medicine for inhibiting varicella-zoster virus |
CN110054584B (en) * | 2019-05-28 | 2022-03-11 | 沈阳药科大学 | 1-aryl-3- {4- [ (pyridin-2-ylmethyl) thio ] phenyl } urea compound and application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003068228A1 (en) * | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Aryl ureas with angiogenesis inhibiting activity |
Family Cites Families (514)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US502504A (en) * | 1893-08-01 | Hermann thoms | ||
DE487014C (en) | 1927-10-23 | 1929-12-09 | I G Farbenindustrie Akt Ges | Process for the preparation of urea derivatives |
US1792156A (en) * | 1928-01-17 | 1931-02-10 | Gen Aniline Works Inc | 5-halogen-2-amino-1-alkyloxy and 1-aralkyloxy-benzenes and intermediate products thereof and process of preparing them |
DE511468C (en) | 1928-01-18 | 1930-10-30 | I G Farbenindustrie Akt Ges | Process for the preparation of 5-chloro-2-amino-1-methoxybenzene |
DE523437C (en) | 1928-12-25 | 1931-05-05 | I G Farbenindustrie Akt Ges | Process for the preparation of 5-chloro- and 5-bromo-2-amino-1-alkyloxy- and 1-aralkyloxybenzenes |
US2093265A (en) | 1931-03-31 | 1937-09-14 | Ici Ltd | Process for the manufacture of diaryl ureas |
US2046375A (en) * | 1931-06-04 | 1936-07-07 | Ici Ltd | p-halogen-omicron-alkoxy-aniline derivatives and process of preparing the same |
US2288422A (en) | 1938-11-11 | 1942-06-30 | Gen Aniline & Film Corp | Mixed ureas |
US2973386A (en) * | 1943-01-05 | 1961-02-28 | Harry A Weldon | Purification of sym dichloro-bis (2, 4, 6-trichlorophenyl)urea |
DE925476C (en) * | 1950-04-29 | 1955-03-21 | Variapat Ag | Process for the preparation of colorless, water-soluble, trifluoromethyl and sulfonic acid groups, aliphatic or aromatic carboxylic acid or sulfonic acid arylides |
US2683082A (en) * | 1950-12-09 | 1954-07-06 | Ethyl Corp | Nu-aryl-nu'-(p-hydroxyphenyl) ureas as antioxidants for petroleum hydrocarbon fuels |
US2722544A (en) | 1950-12-26 | 1955-11-01 | Variapat Ag | Trifluoromethyl halogenated diphenylcarbamide sulfonic acids and their preparation |
US2781330A (en) * | 1953-02-09 | 1957-02-12 | Monsanto Chemicals | Rubber containing urea compound as an anti-exposure cracking agent |
BE527017A (en) * | 1953-03-06 | |||
US2745874A (en) * | 1953-06-18 | 1956-05-15 | Geigy Ag J R | Insecticidal derivatives of diphenyl urea |
GB771333A (en) | 1953-12-22 | 1957-03-27 | Geigy Ag J R | Improvements relating to halogen substituted diphenyl urea and thiourea compounds and their use |
NL193403A (en) * | 1953-12-22 | 1924-02-17 | ||
GB828231A (en) | 1955-10-20 | 1960-02-17 | Geigy Ag J R | Improvements relating to insecticidal compounds and their use |
US2877268A (en) * | 1956-12-24 | 1959-03-10 | Monsanto Chemicals | Substituted ureas |
US2960488A (en) | 1958-04-25 | 1960-11-15 | Eastman Kodak Co | Poly-alpha-olefins containing substituted ureas |
NL254871A (en) | 1959-08-14 | |||
NL277511A (en) | 1961-04-21 | |||
CH428747A (en) | 1961-09-11 | 1967-01-31 | Wander Ag Dr A | Process for the production of new urea and thiourea derivatives |
US3200035A (en) | 1962-06-01 | 1965-08-10 | Ciba Ltd | Treatment of synthetic products, especially synthetic fibers |
US3284433A (en) * | 1963-07-17 | 1966-11-08 | Merck & Co Inc | 4-phenoxy-carbanilides |
FR1457172A (en) | 1964-12-12 | 1966-10-28 | Ferrania Spa | Process for the production of color photographic images and corresponding photographic material |
FR90420E (en) | 1965-06-09 | 1968-02-21 | ||
US3424761A (en) * | 1966-03-07 | 1969-01-28 | Robins Co Inc A H | 3-ureidopyrrolidines |
US3424760A (en) * | 1966-03-07 | 1969-01-28 | Robins Co Inc A H | 3-ureidopyrrolidines |
US3424762A (en) * | 1966-03-07 | 1969-01-28 | Robins Co Inc A H | Certain 3-ureidopyrrolidines |
US3743498A (en) | 1967-10-31 | 1973-07-03 | Du Pont | Method of selectively controlling undesirable vegetation |
US3547940A (en) | 1967-10-31 | 1970-12-15 | Du Pont | Substituted ureido isoxazoles |
SE370866B (en) * | 1968-03-21 | 1974-11-04 | Ciba Geigy Ag | |
DE1768244A1 (en) * | 1968-04-19 | 1971-10-14 | Bayer Ag | N- (2,2,4,4-tetrafluoro-1,3-benz-dioxanyl) ureas and process for their preparation |
US3646059A (en) * | 1969-05-05 | 1972-02-29 | Du Pont | Plant growth regulatory ureidopyrazoles |
US3754887A (en) | 1969-05-05 | 1973-08-28 | Du Pont | Ureidopyrazoles defoliants |
US3668222A (en) | 1969-05-14 | 1972-06-06 | Sandoz Ltd | 11-desacetoxy-wortmannin |
BE754782A (en) | 1969-08-14 | 1971-02-12 | May & Baker Ltd | THIOPHENE DERIVATIVES WITH HERBICIDAL ACTION |
US3823161A (en) | 1970-05-07 | 1974-07-09 | Exxon Research Engineering Co | Aminothiophene derivatives |
US3860645A (en) * | 1973-05-23 | 1975-01-14 | Givaudan Corp | Bacteriostatic substituted carbanilides |
US4212981A (en) * | 1973-07-27 | 1980-07-15 | Shionogi & Co., Ltd. | Process for preparing 3-isoxazolylurea derivatives |
US4111680A (en) * | 1973-07-27 | 1978-09-05 | Shionogi & Co., Ltd. | Herbicidal compositions containing 3-isoxazolylurea derivatives |
US4062861A (en) | 1973-07-27 | 1977-12-13 | Shionogi & Co., Ltd. | 3-Isoxazolylurea derivatives |
JPS5031039A (en) | 1973-07-27 | 1975-03-27 | ||
US4001256A (en) * | 1973-12-26 | 1977-01-04 | The Upjohn Company | Pyridylalkyl phenyl ureas and their n-oxides |
US3931201A (en) | 1974-01-22 | 1976-01-06 | The Dow Chemical Company | Substituted pyridinyloxy(thio)phenyl -acetamides, -ureas and urea derivatives |
US4009847A (en) * | 1974-04-17 | 1977-03-01 | E. I. Du Pont De Nemours And Company | 1-Tertiary-alkyl-3-(substituted thienyl)ureas and 1-tertiary-alkyl-3-(substituted thietyl)ureas as antihypertensive agents |
US3990879A (en) * | 1974-12-26 | 1976-11-09 | Eli Lilly And Company | Method of controlling aquatic weeds |
US4111683A (en) * | 1975-06-27 | 1978-09-05 | Chevron Research Company | N-alkyl or alkoxy-N'-substituted hydrocarbyl urea |
DE2637947C2 (en) * | 1976-08-24 | 1985-09-19 | Bayer Ag, 5090 Leverkusen | Tetrafluoro-1,3-benzodioxanyl-benzoylureas, process for their preparation and their use as insecticides |
JPS5840946B2 (en) * | 1976-10-29 | 1983-09-08 | 石原産業株式会社 | N-benzoyl-N'-pyridyloxyphenylurea compounds, methods for producing them, and insecticides containing them |
US4173637A (en) | 1976-10-29 | 1979-11-06 | Ishihara Sangyo Kaisha Ltd. | N-Benzoyl-N'-pyridyloxy phenyl urea and insecticidal compositions thereof |
US4071524A (en) * | 1976-11-08 | 1978-01-31 | Riker Laboratories, Inc. | Derivatives of urea |
US4183854A (en) * | 1976-11-10 | 1980-01-15 | John Wyeth & Brother Limited | Thiazole compound |
US4042372A (en) * | 1976-11-19 | 1977-08-16 | Eli Lilly And Company | Substituted thiadiazolotriazinediones and method of preparation |
DE2817449A1 (en) | 1978-04-21 | 1979-10-31 | Bayer Ag | MEANS OF REGULATING PLANT GROWTH |
GB1590870A (en) | 1978-05-31 | 1981-06-10 | Shionogi & Co | N-(5-t-butyl-3-isoxazolyl) alkanamide derivatives having herbicidal activity |
JPS5562066A (en) * | 1978-11-03 | 1980-05-10 | Toshihiko Okamoto | N-(2-substituted-4-pyridyl)-urea and thio urea, their preparation and plant growth regulator |
DE2848330A1 (en) * | 1978-11-03 | 1980-05-14 | Schering Ag | METHOD FOR PRODUCING 1,2,3-THIADIAZOL-5-YL UREA |
FI800559A (en) | 1979-03-14 | 1980-09-15 | Hoffmann La Roche | URINAEMNEDERIVAT |
JPS55124763A (en) * | 1979-03-19 | 1980-09-26 | Ishihara Sangyo Kaisha Ltd | 5-trifluoromethyl-2-pyridone derivative |
DE2928485A1 (en) | 1979-07-14 | 1981-01-29 | Bayer Ag | USE OF UREA DERIVATIVES AS A MEDICINAL PRODUCT IN THE TREATMENT OF FATTY METABOLISM DISORDERS |
US4468380A (en) | 1979-12-26 | 1984-08-28 | Eli Lilly And Company | Anticoccidial combinations comprising polyether antibiotics and carbanilides |
BR8106184A (en) * | 1980-01-25 | 1981-11-24 | Reanal Finomvegyszergyar | PROCESS FOR THE PREPARATION OF N-ARYL-N 'DERIVATIVES - (MONO-OR DISSUBSTITUTED) -UREA |
DE3174885D1 (en) | 1981-02-03 | 1986-07-31 | Ici Plc | Process for the extraction of metal values and novel metal extractants |
US4526997A (en) * | 1981-05-06 | 1985-07-02 | Doherty George O P O | Anticoccidial combinations comprising polyether antibiotics and carbanilides |
US4511571A (en) * | 1981-10-20 | 1985-04-16 | Ciba Geigy Corporation | N-(2-Pyridyloxyphenyl)-N'-benzoyl ureas, pesticidal compositions containing same and pesticidal methods of use |
US4473579A (en) * | 1982-01-26 | 1984-09-25 | American Cyanamid Company | Antiatherosclerotic tetrasubstituted ureas and thioureas |
US4623662A (en) | 1985-05-23 | 1986-11-18 | American Cyanamid Company | Antiatherosclerotic ureas and thioureas |
DE3211851A1 (en) * | 1982-03-31 | 1983-10-06 | Basf Ag | DIHYDROTHIOPHENE-CARBONESTER, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE FOR CONTROLLING UNWANTED PLANT GROWTH |
JPS58203957A (en) * | 1982-05-25 | 1983-11-28 | Ube Ind Ltd | Preparation of urea derivative |
IL69621A0 (en) | 1982-09-02 | 1983-12-30 | Duphar Int Res | Pharmaceutical compositions having antitumor activity,comprising certain phenylurea derivatives |
CA1254212A (en) * | 1982-11-12 | 1989-05-16 | Shiro Hirai | Amine derivatives, salts thereof, process for preparing the same and an anti-ulcer agent containing the same |
DE3305866A1 (en) | 1983-02-19 | 1984-08-23 | Basf Ag, 6700 Ludwigshafen | THIOPHEN-CARBONESTER, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE FOR CONTROLLING UNWANTED PLANT GROWTH |
US4499097A (en) * | 1983-03-10 | 1985-02-12 | American Cyanamid Company | 2-(Pyridyl)imidazolyl ketones |
GB8325496D0 (en) * | 1983-09-23 | 1983-10-26 | Hider R C | Pharmaceutical compositions |
US4540566A (en) | 1984-04-02 | 1985-09-10 | Forest Laboratories, Inc. | Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose |
JPS6193163A (en) * | 1984-10-12 | 1986-05-12 | Ishihara Sangyo Kaisha Ltd | N-benzoyl-n'-phenylurea compound, its preparation and carcinostatic agent containing same |
US4727077A (en) | 1985-02-20 | 1988-02-23 | Ishihara Sangyo Kaisha Ltd. | Benzoyl urea compounds, process for their production, and antitumorous compositions containing them |
DE3529247A1 (en) | 1985-05-17 | 1986-11-20 | Bayer Ag, 5090 Leverkusen | USE OF THIENYL UREAS AND ISOHARNS AS AN PERFORMANCE DRIVER IN ANIMALS, NEW THIENYL URINS AND ISOHARNS AND THEIR PRODUCTION |
DE3540377A1 (en) | 1985-11-14 | 1987-05-21 | Bayer Ag | THIENOOXAZINONE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A PERFORMANCE PROVIDER |
DE3541631A1 (en) * | 1985-11-26 | 1987-05-27 | Bayer Ag | SELECTIVE-FUNGICIDAL USE OF THIENYL URINE DERIVATIVES |
AU594098B2 (en) | 1985-12-11 | 1990-03-01 | Ishihara Sangyo Kaisha Ltd. | N-benzoyl urea compounds, antitumorous compositions containing them, and process for their preparation |
EP0230400A3 (en) | 1986-01-21 | 1990-02-14 | Ciba-Geigy Ag | N-3-(5-trifluoromethyl-pyridyl-2-oxy)phenyl-n'-benzoylureas for combating helminths in livestock |
JPS62185013A (en) | 1986-02-08 | 1987-08-13 | Green Cross Corp:The | Easily absorbable pharmaceutical composition |
DE3612830A1 (en) | 1986-04-16 | 1987-10-22 | Basf Ag | THIADIAZOLYL URINE CONTAINING AGENT FOR DEBELING PLANTS |
DE3785507T2 (en) * | 1986-07-31 | 1993-07-29 | Beecham Group Plc | AZABICYCLIC COMPOUNDS, METHOD FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL USE. |
NZ221964A (en) * | 1986-10-03 | 1990-03-27 | Ishihara Sangyo Kaisha | Benzoylurea compounds and insecticidal compositions |
EP0264904A3 (en) | 1986-10-23 | 1988-08-17 | Ishihara Sangyo Kaisha, Ltd. | Pharmaceutical compositions containing benzoyl urea derivatives |
DE3636190A1 (en) * | 1986-10-24 | 1988-04-28 | Bayer Ag | METHOD FOR PRODUCING N, N-DIARYL UREAS |
JPH06100808B2 (en) | 1987-05-28 | 1994-12-12 | 富士写真フイルム株式会社 | Processing method of silver halide color photographic light-sensitive material |
DE3853662D1 (en) | 1987-10-16 | 1995-06-01 | Ciba Geigy Ag | Pesticides. |
DE3810382A1 (en) | 1988-03-26 | 1989-10-12 | Bayer Ag | 5-AMINO-1-PHENYLPYRAZOLE, METHOD AND 5-HALOGEN-1-PHENYLPYRAZOLE AS INTERMEDIATE PRODUCTS FOR THE PRODUCTION THEREOF AND THEIR USE AS HERBICIDES |
WO1990002112A1 (en) | 1988-08-23 | 1990-03-08 | The Nutrasweet Company | Substituted aryl ureas as high potency sweeteners |
JPH0278699A (en) | 1988-09-12 | 1990-03-19 | Green Cross Corp:The | Benzoylurea compound-albumin complex |
FR2662692B1 (en) | 1990-05-30 | 1995-04-28 | Novapharme | HETEROCYCLIC DERIVATIVES WITH ANTICONVULSIVE ACTIVITY, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION. |
FR2639636B1 (en) | 1988-11-30 | 1994-03-04 | Novapharme | NOVEL HETEROCYCLIC COMPOUNDS WITH ANTICONVULSIVE ACTIVITY, PREPARATION METHOD AND THERAPEUTIC COMPOSITIONS CONTAINING THEM |
JPH02196719A (en) * | 1989-01-24 | 1990-08-03 | Green Cross Corp:The | Powdery drug composition |
JPH02237922A (en) | 1989-01-24 | 1990-09-20 | Green Cross Corp:The | Antiviral agent |
EP0379915A1 (en) | 1989-01-26 | 1990-08-01 | Bayer Ag | Substituted phenoxybenzonitrile derivatives, processes for their preparation and their use as herbicides and plant growth regulators |
JP3002204B2 (en) * | 1989-03-13 | 2000-01-24 | 株式会社東芝 | Time-series signal recognition device |
US4973675A (en) | 1989-04-13 | 1990-11-27 | University Of Tennessee Research Center | Hybrid nitrosoureidoanthracyclines having antitumor activity |
JPH0395153A (en) | 1989-06-15 | 1991-04-19 | Mitsubishi Kasei Corp | Diphenyl urea derivative |
US5665543A (en) | 1989-07-18 | 1997-09-09 | Oncogene Science, Inc. | Method of discovering chemicals capable of functioning as gene expression modulators |
IL95860A0 (en) | 1989-10-13 | 1991-07-18 | Ciba Geigy Ag | Thienylthioureas,-isothioureas and-carbodiimides |
US5177110A (en) * | 1989-10-27 | 1993-01-05 | Ciba-Geigy Corporation | Injectable parasiticidal composition |
EP0425443A1 (en) | 1989-10-27 | 1991-05-02 | Ciba-Geigy Ag | Injectable antiparasitic agent |
CA2051705A1 (en) * | 1990-06-19 | 1991-12-20 | Kiyoaki Katano | Pyridine derivatives having angiotensin ii antagonism |
US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
GB9017892D0 (en) | 1990-08-15 | 1990-09-26 | May & Baker Ltd | New compositions of matter |
PT98990A (en) | 1990-09-19 | 1992-08-31 | American Home Prod | PROCESS FOR THE PREPARATION OF CARBOXYLIC ACID ESTERS OF RAPAMICIN |
US5319099A (en) | 1991-01-21 | 1994-06-07 | Shionogi Seiyaku Kabushiki Kaisha | 3-benzylidene-1-carbamoyl-2-pyrrolidone compounds useful as antiinflammatory agents |
JP2671693B2 (en) | 1991-03-04 | 1997-10-29 | 松下電器産業株式会社 | Biosensor and manufacturing method thereof |
US5120842A (en) | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
US5185438A (en) * | 1991-04-02 | 1993-02-09 | The Trustees Of Princeton University | Nucleic acids encoding hencatoporetic stem cell receptor flk-2 |
US5270458A (en) | 1991-04-02 | 1993-12-14 | The Trustees Of Princeton University | Nucleic acids encoding fragments of hematopoietic stem cell receptor flk-2 |
US5100883A (en) * | 1991-04-08 | 1992-03-31 | American Home Products Corporation | Fluorinated esters of rapamycin |
FI921595A (en) | 1991-04-17 | 1992-10-18 | American Home Prod | RAPAMYCINKARBAMATER |
US5118678A (en) | 1991-04-17 | 1992-06-02 | American Home Products Corporation | Carbamates of rapamycin |
US5721237A (en) * | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
US5118677A (en) | 1991-05-20 | 1992-06-02 | American Home Products Corporation | Amide esters of rapamycin |
US5162360A (en) | 1991-06-24 | 1992-11-10 | Warner-Lambert Company | 2-heteroatom containing urea and thiourea ACAT inhibitors |
US5185358A (en) * | 1991-06-24 | 1993-02-09 | Warner-Lambert Co. | 3-heteroatom containing urea and thiourea ACAT inhibitors |
WO1993004170A1 (en) * | 1991-08-23 | 1993-03-04 | The United States Of America Represented By The Secretary, Department Of Health And Human Services | Raf protein kinase therapeutics |
US5151413A (en) | 1991-11-06 | 1992-09-29 | American Home Products Corporation | Rapamycin acetals as immunosuppressant and antifungal agents |
CA2123133C (en) | 1991-11-07 | 2005-01-04 | Michael J. Heller | Hybridization of polynucleotides conjugated with chromophores and fluorophores to generate donor-to-donor energy transfer system |
FR2683818B1 (en) | 1991-11-14 | 1993-12-31 | Adir Cie | NOVEL 3-SULFONYLAMINO-2- (1H) -QUINOLEINONE DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
US5348853A (en) | 1991-12-16 | 1994-09-20 | Biotronics Corporation | Method for reducing non-specific priming in DNA amplification |
US5508288A (en) * | 1992-03-12 | 1996-04-16 | Smithkline Beecham, P.L.C. | Indole derivatives as 5HT1C antagonists |
DE4212407A1 (en) | 1992-04-13 | 1993-10-14 | Knorr Bremse Gmbh | Air gap detector for a compressed air operated disc brake |
US5312820A (en) | 1992-07-17 | 1994-05-17 | Merck & Co., Inc. | Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines |
ZA935112B (en) | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
ZA935111B (en) | 1992-07-17 | 1994-02-04 | Smithkline Beecham Corp | Rapamycin derivatives |
WO1994004541A2 (en) | 1992-08-12 | 1994-03-03 | The Upjohn Company | Protein kinase inhibitors and related compounds combined with taxol |
US5256790A (en) | 1992-08-13 | 1993-10-26 | American Home Products Corporation | 27-hydroxyrapamycin and derivatives thereof |
JP2717481B2 (en) | 1992-08-25 | 1998-02-18 | 富士写真フイルム株式会社 | Silver halide color photographic materials |
WO1994009156A1 (en) | 1992-10-08 | 1994-04-28 | The Regents Of The University Of California | Pcr assays to determine the presence and concentration of a target |
US5258389A (en) | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
US6177401B1 (en) * | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
WO1994014801A1 (en) | 1992-12-29 | 1994-07-07 | Smithkline Beecham Plc | Heterocyclic urea derivatives as 5ht2c and 5ht2b antagonists |
US5512473A (en) | 1993-01-29 | 1996-04-30 | Brent; Roger | Max-interacting proteins and related molecules and methods |
GB9302275D0 (en) | 1993-02-05 | 1993-03-24 | Smithkline Beecham Plc | Novel compounds |
TW272942B (en) | 1993-02-10 | 1996-03-21 | Takeda Pharm Industry Co Ltd | |
DK41193D0 (en) | 1993-04-07 | 1993-04-07 | Neurosearch As | ion channel openers |
AU6633694A (en) | 1993-04-09 | 1994-11-08 | Board Of Regents Of The University Of Nebraska, The | Novel methods and compositions for the treatment of (ras)-activated cancer with heterotypic anti-(raf) antisense oligonucleotides |
GB9308802D0 (en) | 1993-04-28 | 1993-06-09 | Smithkline Beecham Plc | Treatment |
DE4322806A1 (en) | 1993-07-08 | 1995-01-12 | Janich Gmbh & Co | Device for sealing between two parts of the system |
IL110296A (en) | 1993-07-16 | 1999-12-31 | Smithkline Beecham Corp | Imidazole compounds process for their preparation and pharmaceutical compositions containing them |
US5378725A (en) * | 1993-07-19 | 1995-01-03 | The Arizona Board Of Regents | Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof |
US6514745B1 (en) * | 1993-07-19 | 2003-02-04 | The Regents Of The University Of California | Oncoprotein protein kinase |
NZ264063A (en) * | 1993-08-13 | 1995-11-27 | Nihon Nohyaku Co Ltd | N-(2-phenylpyrid-3-yl)- and n-(4-phenylpyrimidin-5-yl)-n'-phenylurea derivatives and pharmaceutical compositions |
US5441947A (en) | 1993-08-25 | 1995-08-15 | Eli Lilly And Company | Methods of inhibiting vascular restenosis |
US5468773A (en) | 1993-08-25 | 1995-11-21 | Eli Lilly And Company | Methods for inhibiting bone loss and cartilage degradation using wortmannin and its analogs |
US5869043A (en) * | 1993-09-17 | 1999-02-09 | Smithkline Beecham Corporation | Drug binding protein |
US6361773B1 (en) * | 1993-09-17 | 2002-03-26 | Smithkline Beecham Corporation | Antibodies produced against cytokine suppressive anti-inflammatory drug binding proteins |
US5783664A (en) | 1993-09-17 | 1998-07-21 | Smithkline Beecham Corporation | Cytokine suppressive anit-inflammatory drug binding proteins |
DE69421624T2 (en) | 1993-09-17 | 2000-07-20 | Smithkline Beecham Corp | MEDICINE BINDING PROTEIN |
US5547966A (en) | 1993-10-07 | 1996-08-20 | Bristol-Myers Squibb Company | Aryl urea and related compounds |
CA2133815A1 (en) * | 1993-10-12 | 1995-04-13 | Jeffrey Alan Dodge | Inhibition of phosphatidylinositol 3-kinase with viridin, demethoxyviridin, viridiol, demethoxyviridiol, virone, wortmannolone, and analogs thereof |
US5596001A (en) * | 1993-10-25 | 1997-01-21 | Pfizer Inc. | 4-aryl-3-(heteroarylureido)quinoline derivatves |
EP1306377A3 (en) | 1993-11-08 | 2003-05-07 | Smithkline Beecham Corporation | Pyridyl-oxazoles and their use as cytokines inhibitors |
US5538848A (en) | 1994-11-16 | 1996-07-23 | Applied Biosystems Division, Perkin-Elmer Corp. | Method for detecting nucleic acid amplification using self-quenching fluorescence probe |
JPH07141053A (en) | 1993-11-17 | 1995-06-02 | Nec Niigata Ltd | Clock generating circuit |
CA2175215C (en) | 1993-11-19 | 2008-06-03 | Yat Sun Or | Semisynthetic analogs of rapamycin (macrolides) being immunomodulators |
NZ277498A (en) | 1993-12-17 | 1998-03-25 | Novartis Ag | Rapamycin derivatives |
US5700823A (en) | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
CH686211A5 (en) | 1994-01-27 | 1996-02-15 | Ciba Geigy Ag | Moth and Koferschutzmittel. |
US6524832B1 (en) | 1994-02-04 | 2003-02-25 | Arch Development Corporation | DNA damaging agents in combination with tyrosine kinase inhibitors |
US6811779B2 (en) | 1994-02-10 | 2004-11-02 | Imclone Systems Incorporated | Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy |
DE4412334A1 (en) | 1994-04-11 | 1995-10-19 | Hoechst Ag | Substituted N-heteroaroylguanidines, process for their preparation, their use as a medicament or diagnostic agent, and medicament containing them |
US5871918A (en) | 1996-06-20 | 1999-02-16 | The University Of North Carolina At Chapel Hill | Electrochemical detection of nucleic acid hybridization |
CA2159830C (en) | 1994-04-29 | 2001-07-03 | Timothy M Woudenberg | System for real time detection of nucleic acid amplification products |
US5559137A (en) | 1994-05-16 | 1996-09-24 | Smithkline Beecham Corp. | Compounds |
US5744362A (en) | 1994-05-31 | 1998-04-28 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
US5563255A (en) * | 1994-05-31 | 1996-10-08 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
US5656612A (en) | 1994-05-31 | 1997-08-12 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
WO1995033458A1 (en) | 1994-06-02 | 1995-12-14 | Smithkline Beecham Corporation | Anti-inflammatory compounds |
US5470882A (en) | 1994-06-02 | 1995-11-28 | Smithkline Beecham Corp. | Anti-inflammatory compounds |
US5447957A (en) | 1994-06-02 | 1995-09-05 | Smithkline Beecham Corp. | Anti-inflammatory compounds |
US5786362A (en) | 1994-06-16 | 1998-07-28 | University Of Miami | Method of treating Hormone independent cancer |
EP0690344A1 (en) | 1994-06-29 | 1996-01-03 | Konica Corporation | Silver halide color photographic light-sensitive material |
US5480906A (en) * | 1994-07-01 | 1996-01-02 | Eli Lilly And Company | Stereochemical Wortmannin derivatives |
FR2722319B1 (en) | 1994-07-08 | 1996-08-14 | Thomson Csf | COLOR DISPLAY DEVICE |
US5597719A (en) * | 1994-07-14 | 1997-01-28 | Onyx Pharmaceuticals, Inc. | Interaction of RAF-1 and 14-3-3 proteins |
ATE220661T1 (en) | 1994-10-19 | 2002-08-15 | Novartis Erfind Verwalt Gmbh | ANTIVIRAL ETHERS OF ASPARTATE PROTEASE SUBSTRATE ISOSTERS |
JP3591938B2 (en) | 1994-10-27 | 2004-11-24 | キヤノン株式会社 | Ink jet recording medium and image forming method using the same |
CA2161376C (en) * | 1994-10-27 | 2005-01-11 | Toshiaki Minami | Reversible multi-color thermal recording medium |
AU3698095A (en) | 1994-10-28 | 1996-05-23 | Novo Nordisk A/S | A process for chemical finishing of insoluble polymers |
US5723290A (en) | 1994-11-03 | 1998-03-03 | Trustees Of The University Of Pennsylvania | Methods for profiling mRNA expression in neurites |
TW313568B (en) | 1994-12-20 | 1997-08-21 | Hoffmann La Roche | |
US5780483A (en) | 1995-02-17 | 1998-07-14 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
EP0809492A4 (en) | 1995-02-17 | 2007-01-24 | Smithkline Beecham Corp | Il-8 receptor antagonists |
US5624937A (en) | 1995-03-02 | 1997-04-29 | Eli Lilly And Company | Chemical compounds as inhibitors of amyloid beta protein production |
US5814646A (en) | 1995-03-02 | 1998-09-29 | Eli Lilly And Company | Inhibitors of amyloid beta-protein production |
DE19512639A1 (en) | 1995-04-05 | 1996-10-10 | Merck Patent Gmbh | Benzonitriles and fluorides |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5710173A (en) | 1995-06-07 | 1998-01-20 | Sugen, Inc. | Thienyl compounds for inhibition of cell proliferative disorders |
US5658903A (en) | 1995-06-07 | 1997-08-19 | Smithkline Beecham Corporation | Imidazole compounds, compositions and use |
US5773459A (en) | 1995-06-07 | 1998-06-30 | Sugen, Inc. | Urea- and thiourea-type compounds |
PT833828E (en) | 1995-06-09 | 2003-02-28 | Novartis Ag | RAPAMICINE DERIVATIVES |
US5994063A (en) | 1995-06-23 | 1999-11-30 | Metzker; Michael L. | Substituted 4,4-difluoro-4-bora-3A,4A-diaza-s-indacene compounds for homogenous amplification/detection assays |
GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
US5849761A (en) | 1995-09-12 | 1998-12-15 | Regents Of The University Of California | Peripherally active anti-hyperalgesic opiates |
ZA967840B (en) * | 1995-09-18 | 1997-04-07 | Sankyo Co | New urea derivatives having a cat inhibitory activity their preparation and their therapeutic and prophylactic use |
SE510846C2 (en) | 1995-11-06 | 1999-06-28 | Moelnlycke Health Care Ab | Inner packaging for in an outer package sterile-packed abdominal cloths |
US6143764A (en) | 1995-11-07 | 2000-11-07 | Kirin Beer Kabushiki Kaisha | Quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation and pharmaceutical compositions containing the same |
EP0881217A4 (en) * | 1995-12-28 | 2000-01-26 | Kureha Chemical Ind Co Ltd | Process for producing pyridinecarboxamides or thiocarboxamides |
US5807876A (en) | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
US6005008A (en) | 1996-02-16 | 1999-12-21 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
US6011029A (en) | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
US6103692A (en) | 1996-03-12 | 2000-08-15 | The General Hospital Corporation | Inhibiting protein interactions |
US6262113B1 (en) | 1996-03-20 | 2001-07-17 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
US6211373B1 (en) | 1996-03-20 | 2001-04-03 | Smithkline Beecham Corporation | Phenyl urea antagonists of the IL-8 receptor |
DE69701298T2 (en) | 1996-04-15 | 2000-10-05 | Takeda Chemical Industries Ltd | Hydroxypyridine derivatives, their preparation and their pharmaceutical use |
CN1116288C (en) | 1996-04-23 | 2003-07-30 | 沃泰克斯药物股份有限公司 | Urea derivatives as inhibitors of IMPDH enzyme |
US6232299B1 (en) | 1996-05-01 | 2001-05-15 | Eli Lilly And Company | Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy |
JPH09301858A (en) | 1996-05-13 | 1997-11-25 | Senju Pharmaceut Co Ltd | Aqueous medicine containing stabilized cholorohexidine gluconate |
EP0906273B1 (en) | 1996-05-24 | 2002-10-16 | Neurosearch A/S | Phenyl derivatives containing an acidic group, their preparation and their use as chloride channel blockers |
US5910417A (en) | 1996-05-31 | 1999-06-08 | National Jewish Center For Immunology And Respiratory Medicine | Regulation of cytokine production in a hematopoietic cell |
EP0915651A4 (en) | 1996-06-27 | 2001-10-24 | Smithkline Beecham Corp | Il-8 receptor antagonists |
EP0932405A4 (en) | 1996-06-27 | 2001-10-17 | Smithkline Beckman Corp | Il-8 receptor antagonists |
JP2000513359A (en) | 1996-06-27 | 2000-10-10 | スミスクライン・ビーチャム・コーポレイション | IL-8 receptor antagonist |
US6133319A (en) | 1996-06-27 | 2000-10-17 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
PL325341A1 (en) | 1996-06-29 | 1998-07-20 | Samjin Pharmaceutical Co | Derivatives od piperazine and method of obtaining them |
US6117635A (en) | 1996-07-16 | 2000-09-12 | Intergen Company | Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon |
US6150415A (en) | 1996-08-13 | 2000-11-21 | The Regents Of The University Of California | Epoxide hydrolase complexes and methods therewith |
US5808080A (en) | 1996-09-05 | 1998-09-15 | Eli Lilly And Company | Selective β3 adrenergic agonists |
WO1998017207A1 (en) | 1996-10-21 | 1998-04-30 | Synthes Ag Chur | Surgical prosthetic device |
US5965573A (en) | 1996-10-23 | 1999-10-12 | Zymogenetics, Inc. | Compositions and methods for treating bone deficit conditions |
EP0973513A4 (en) | 1996-10-23 | 2003-03-19 | Zymogenetics Inc | Compositions and methods for treating bone deficit conditions |
WO1998020868A1 (en) | 1996-11-15 | 1998-05-22 | The Picower Institute For Medical Research | Guanylhydrazones useful for treating diseases associated with t cell activation |
GB9623833D0 (en) | 1996-11-16 | 1997-01-08 | Zeneca Ltd | Chemical compound |
WO1998022432A1 (en) | 1996-11-18 | 1998-05-28 | Yamanouchi Pharmaceutical Co., Ltd. | Novel acylamino-substituted acylanilide derivatives or pharmaceutical composition comprising the same |
FR2755967B1 (en) * | 1996-11-21 | 1999-01-29 | Pf Medicament | PYRIDIN-2-YL-METHYLAMINE DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS MEDICAMENTS |
US5929250A (en) | 1997-01-23 | 1999-07-27 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
HUP0001943A3 (en) | 1997-01-23 | 2002-12-28 | Smithkline Beecham Corp | Benzimidazole and benzotriazole derivatives, their use, process for their preparation and pharmaceutical compositions containing them |
WO1998034929A1 (en) | 1997-02-12 | 1998-08-13 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
US20020111495A1 (en) | 1997-04-04 | 2002-08-15 | Pfizer Inc. | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes |
EA003528B1 (en) | 1997-04-04 | 2003-06-26 | Пфайзер Продактс Инк. | Nicotinamide derivatives, use thereof, pharmaceutical composition, method of treatment and method for selective inhibition of pde4 d isoenzymes |
DE69830751T2 (en) | 1997-04-10 | 2006-05-18 | Pharmacia & Upjohn Co. Llc, Kalamazoo | Polyaromatic compounds for the treatment of herpes infections |
AU7080298A (en) | 1997-04-25 | 1998-11-24 | Takeda Chemical Industries Ltd. | Triazine derivatives, their production and agrochemical composition |
US6210710B1 (en) * | 1997-04-28 | 2001-04-03 | Hercules Incorporated | Sustained release polymer blend for pharmaceutical applications |
AR012634A1 (en) * | 1997-05-02 | 2000-11-08 | Sugen Inc | QUINAZOLINE BASED COMPOUND, FAMACEUTICAL COMPOSITION THAT UNDERSTANDS IT, METHOD TO SYNTHESIZE IT, ITS USE, METHODS OF MODULATION OF THE DESERINE / TREONIN PROTEIN-KINASE FUNCTION AND IN VITRO METHOD TO IDENTIFY COMPOUNDS THAT MODULATE |
US6316479B1 (en) | 1997-05-19 | 2001-11-13 | Sugen, Inc. | Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders |
WO1998052937A2 (en) | 1997-05-22 | 1998-11-26 | G.D. Searle And Co. | 4-aryl-3(5)-heteroaryl substituted pyrazoles as p38 kinase |
WO1998052941A1 (en) | 1997-05-22 | 1998-11-26 | G.D. Searle And Co. | PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS |
US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
WO1998052558A1 (en) | 1997-05-23 | 1998-11-26 | Bayer Corporation | INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS |
US6344476B1 (en) * | 1997-05-23 | 2002-02-05 | Bayer Corporation | Inhibition of p38 kinase activity by aryl ureas |
US6187799B1 (en) | 1997-05-23 | 2001-02-13 | Onyx Pharmaceuticals | Inhibition of raf kinase activity using aryl ureas |
ATE399007T1 (en) | 1997-05-23 | 2008-07-15 | Bayer Pharmaceuticals Corp | RAF KINASE INHIBITOR |
US6150395A (en) | 1997-05-30 | 2000-11-21 | The Regents Of The University Of California | Indole-3-carbinol (I3C) derivatives and methods |
US5985592A (en) * | 1997-06-05 | 1999-11-16 | Dalhousie University | Uses for pentoxifylline or functional derivatives/metabolites thereof |
US6294350B1 (en) | 1997-06-05 | 2001-09-25 | Dalhousie University | Methods for treating fibroproliferative diseases |
JP2002504909A (en) | 1997-06-13 | 2002-02-12 | スミスクライン・ビーチャム・コーポレイション | New substituted pyrazole and pyrazoline compounds |
US6159901A (en) | 1997-06-27 | 2000-12-12 | Kureha Kagaku Kogyo Kabushiki Kaisha | 6-phenoxy picolinic acid alkylidene hydrazide derivative, process for producing the same and herbicide using the same |
US6093742A (en) | 1997-06-27 | 2000-07-25 | Vertex Pharmaceuticals, Inc. | Inhibitors of p38 |
US6525065B1 (en) * | 1997-06-30 | 2003-02-25 | Targacept, Inc. | Pharmaceutical compositions and methods for effecting dopamine release |
AUPP003197A0 (en) | 1997-09-03 | 1997-11-20 | Fujisawa Pharmaceutical Co., Ltd. | New heterocyclic compounds |
UA71555C2 (en) * | 1997-10-06 | 2004-12-15 | Zentaris Gmbh | Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives |
AU9802198A (en) | 1997-10-21 | 1999-05-10 | Pharmacia & Upjohn Company | Antiinflammatory thiadiazolyl ureas which act as lfa-1 and mac-1 inhibitors |
PT1027328E (en) | 1997-10-31 | 2006-11-30 | Aventis Pharma Ltd | Substituted anilides |
WO1999023091A1 (en) | 1997-11-03 | 1999-05-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as anti-inflammatory agents |
US6022884A (en) | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
US6018065A (en) | 1997-11-10 | 2000-01-25 | Advanced Technology Materials, Inc. | Method of fabricating iridium-based materials and structures on substrates, iridium source reagents therefor |
IL135176A0 (en) | 1997-11-10 | 2001-05-20 | Bristol Myers Squibb Co | Benzothiazole derivatives and pharmaceutical compositions containing the same |
GB9723789D0 (en) | 1997-11-12 | 1998-01-07 | Zeneca Ltd | Chemical compounds |
WO1999026657A1 (en) | 1997-11-25 | 1999-06-03 | Musc Foundation For Research Development | Inhibitors of nitric oxide synthase |
WO1999028305A1 (en) | 1997-12-01 | 1999-06-10 | E.I. Du Pont De Nemours And Company | Fungicidal cyclic amides |
US6635421B1 (en) | 1997-12-09 | 2003-10-21 | Children's Medical Center Corporation | Neuropilins and use thereof in methods for diagnosis and prognosis of cancer |
US6174901B1 (en) * | 1998-12-18 | 2001-01-16 | Amgen Inc. | Substituted pyridine and pyridazine compounds and methods of use |
SK282727B6 (en) | 1997-12-19 | 2002-11-06 | Slovakofarma, A. S. | 1,3-Disubstituted ureas - ACAT inhibitors and method of preparing |
US7517880B2 (en) | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
KR100622138B1 (en) | 1997-12-22 | 2006-09-13 | 바이엘 코포레이션 | Inhibition of raf kinase using aryl and heteroaryl substituted heterocyclic ureas |
US7329670B1 (en) * | 1997-12-22 | 2008-02-12 | Bayer Pharmaceuticals Corporation | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas |
US20120046290A1 (en) * | 1997-12-22 | 2012-02-23 | Jacques Dumas | Inhibition of p38 kinase activity using substituted heterocyclic ureas |
CN1213022C (en) | 1997-12-22 | 2005-08-03 | 拜尔有限公司 | Inhibition of raf kinase using symmerical and unsymmerical substituted diphenyl ureas |
CZ299156B6 (en) | 1997-12-22 | 2008-05-07 | Bayer Corporation | Substituted heterocyclic ureas, pharmaceutical compositions in which they are comprised and their use |
US20080300281A1 (en) | 1997-12-22 | 2008-12-04 | Jacques Dumas | Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas |
WO1999032111A1 (en) | 1997-12-22 | 1999-07-01 | Bayer Corporation | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS |
ES2155817T3 (en) | 1997-12-22 | 2007-06-16 | Bayer Pharmaceuticals Corp. | INHIBITION OF THE ACTIVITY OF QUINASA P38 USING HETEROCICLIC UREAS REPLACED WITH ARILO AND HETEROARILO. |
US20070244120A1 (en) | 2000-08-18 | 2007-10-18 | Jacques Dumas | Inhibition of raf kinase using substituted heterocyclic ureas |
ATE297383T1 (en) | 1997-12-22 | 2005-06-15 | Bayer Pharmaceuticals Corp | INHIBITION OF P38 KINASE USING SYMMETRIC AND ASYMMETRIC DIPHENYL UREASES |
WO1999032109A1 (en) | 1997-12-23 | 1999-07-01 | Bristol-Myers Squibb Company | 7-deoxy-6-nitrogen substituted paclitaxels |
EP1043020A1 (en) | 1997-12-25 | 2000-10-11 | Daiichi Pharmaceutical Co., Ltd. | Medicinal composition for percutaneous administration |
GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
US6221913B1 (en) | 1998-01-21 | 2001-04-24 | Zymogenetics, Inc. | Dialkyl ureas as calcitonin mimetics |
FR2774824B1 (en) | 1998-02-09 | 2000-04-28 | Moving Magnet Tech | IMPROVED LINEAR ACTUATOR |
ATE238554T1 (en) * | 1998-02-18 | 2003-05-15 | Theryte Ltd | CANCER TREATMENT |
MY132496A (en) | 1998-05-11 | 2007-10-31 | Vertex Pharma | Inhibitors of p38 |
US6413773B1 (en) * | 1998-06-01 | 2002-07-02 | The Regents Of The University Of California | Phosphatidylinositol 3-kinase inhibitors as stimulators of endocrine differentiation |
UA60365C2 (en) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Isothiazole derivatives, a method for preparing thereof, a pharmaceutical composition and a method for treatment of hyperproliferative disease of mammal |
US6667340B1 (en) | 1998-06-26 | 2003-12-23 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Inhibitors of phosphatidyl myo-inositol cycle |
US6352977B1 (en) * | 1998-07-13 | 2002-03-05 | Aventis Pharma Limited | Substituted β-alanines |
US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
JP2002526482A (en) | 1998-09-18 | 2002-08-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | inhibitors of p38 |
US6383734B1 (en) | 1998-09-30 | 2002-05-07 | Advanced Research And Technology Institute, Inc. | Method to determine inhibition of PAK3 activation of Raf-1 |
US6130053A (en) | 1999-08-03 | 2000-10-10 | Cell Pathways, Inc. | Method for selecting compounds for inhibition of neoplastic lesions |
GB9823873D0 (en) | 1998-10-30 | 1998-12-30 | Pharmacia & Upjohn Spa | 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents |
JP2002529421A (en) | 1998-11-06 | 2002-09-10 | ビーエーエスエフ アクチェンゲゼルシャフト | Methods for inhibiting vascular hyperpermeability |
IL143328A0 (en) | 1998-11-25 | 2002-04-21 | Genetica Inc | Methods and reagents for increasing proliferative capacity and preventing replicative senescence |
US6114517A (en) | 1998-12-10 | 2000-09-05 | Isis Pharmaceuticals Inc. | Methods of modulating tumor necrosis factor α-induced expression of cell adhesion molecules |
WO2000035455A1 (en) | 1998-12-15 | 2000-06-22 | Telik, Inc. | Heteroaryl-aryl ureas as igf-1 receptor antagonists |
UY25842A1 (en) | 1998-12-16 | 2001-04-30 | Smithkline Beecham Corp | IL-8 RECEPTOR ANTAGONISTS |
AU3126700A (en) | 1998-12-18 | 2000-07-03 | Du Pont Pharmaceuticals Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
US6331541B1 (en) * | 1998-12-18 | 2001-12-18 | Soo S. Ko | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
US6147107A (en) | 1998-12-20 | 2000-11-14 | Virginia Commonwealth University | Specific inhibition of the P42/44 mitogen activated protein (map) kinase cascade sensitizes tumor cells |
US20080269265A1 (en) | 1998-12-22 | 2008-10-30 | Scott Miller | Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas |
GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
DE69926542T2 (en) | 1998-12-25 | 2006-04-27 | Teikoku Hormone Mfg. Co., Ltd. | aminopyrazole |
US6351764B1 (en) | 1998-12-31 | 2002-02-26 | Michael Voticky | System and method for prioritizing communications messages |
US7351834B1 (en) | 1999-01-13 | 2008-04-01 | Bayer Pharmaceuticals Corporation | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
EP1140840B1 (en) | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US20020065296A1 (en) | 1999-01-13 | 2002-05-30 | Bayer Corporation | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
JP2002534468A (en) * | 1999-01-13 | 2002-10-15 | バイエル コーポレイション | ω-Carboxyaryl-substituted diphenylureas as p38 kinase inhibitors |
US7928239B2 (en) | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
TWI284642B (en) | 1999-01-18 | 2007-08-01 | Hoffmann La Roche | Novel heterocyclic sulfonamides |
UA73492C2 (en) | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
NZ513006A (en) | 1999-01-22 | 2003-10-31 | Kirin Brewery | Quinoline derivatives and quinazoline derivatives |
ES2226785T3 (en) | 1999-02-12 | 2005-04-01 | Smithkline Beecham Plc | DERIVATIVES OF FENILUREA AS ANTAGONISTS OF THE RECEIVERS OF OREXINA. |
EP1157026A1 (en) | 1999-02-22 | 2001-11-28 | Boehringer Ingelheim Pharmaceuticals Inc. | Polycyclo heterocyclic derivatives as antiinflammatory agents |
DE60014603T2 (en) | 1999-03-12 | 2006-02-16 | Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield | Heterocyclic urea and related compounds as anti-inflammatory agents |
DE60023853T2 (en) | 1999-03-12 | 2006-05-24 | Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield | AROMATIC HETEROCYCLIC COMPOUNDS OF ANTI-INFLAMMATORY ACTIVE SUBSTANCES |
IL145475A0 (en) | 1999-03-19 | 2002-06-30 | Vertex Pharma | Compounds that inhibit impdh enzyme and pharmaceutical compositions containing the same |
BR0009322A (en) | 1999-03-26 | 2002-04-30 | Euro Celtique Sa | Pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles replaced with aryl and their use |
US6140124A (en) | 1999-04-06 | 2000-10-31 | Isis Pharmaceuticals Inc. | Antisense modulation of P38 mitogen activated protein kinase expression |
US6316462B1 (en) | 1999-04-09 | 2001-11-13 | Schering Corporation | Methods of inducing cancer cell death and tumor regression |
AU4591800A (en) | 1999-05-05 | 2000-11-21 | Aventis Pharma Limited | Ureas as cell adhesion modulators |
IL146480A0 (en) | 1999-05-14 | 2002-07-25 | Imclone Systems Inc | Treatment of refractory human tumors with epidermal growth factor receptor antagonists |
HN2000000051A (en) | 1999-05-19 | 2001-02-02 | Pfizer Prod Inc | USEFUL HETEROCICLIC DERIVATIVES AS ANTI-TARGET AGENTS |
TWI234557B (en) | 1999-05-26 | 2005-06-21 | Telik Inc | Novel naphthalene ureas as glucose uptake enhancers |
DE19927835A1 (en) | 1999-06-18 | 2000-12-21 | Clariant Gmbh | Use of improved cyan pigments in electrophotographic toners and developers, powder coatings and ink jet inks |
DE60024830T2 (en) | 1999-07-09 | 2006-06-14 | Boehringer Ingelheim Pharma | METHOD FOR PRODUCING HETEROARYL SUBSTITUTED UREA BONDING |
ES2251395T3 (en) | 1999-07-26 | 2006-05-01 | Banyu Pharmaceutical Co., Ltd. | BIARILURE DERIVATIVES. |
ES2260036T3 (en) | 1999-07-28 | 2006-11-01 | Kirin Beer Kabushiki Kaisha | DERIVATIVES OF UREA AS INHIBITORS OF THE CCR-3 RECEIVER. |
US6387900B1 (en) | 1999-08-12 | 2002-05-14 | Pharmacia & Upjohn S.P.A. | 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents |
US6372933B1 (en) | 1999-08-26 | 2002-04-16 | Smithkline Beecham Corporation | Process for preparing certain phenyl urea compounds |
EP1220688A1 (en) | 1999-10-15 | 2002-07-10 | The van Kampen Group, Inc. | Treatment of dermal tumors, warts, and viral infections using heat-killed p. acnes |
US6420378B1 (en) | 1999-10-15 | 2002-07-16 | Supergen, Inc. | Inhibition of abnormal cell proliferation with camptothecin and combinations including the same |
US6794393B1 (en) | 1999-10-19 | 2004-09-21 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
WO2001036403A1 (en) | 1999-11-16 | 2001-05-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Urea derivatives as anti-inflammatory agents |
US8815517B2 (en) * | 1999-12-28 | 2014-08-26 | Ribonomics, Inc. | Methods for identifying functionally related genes and drug targets |
AU2464601A (en) | 1999-12-29 | 2001-07-09 | Wyeth | Tricyclic protein kinase inhibitors |
WO2001051928A1 (en) * | 2000-01-12 | 2001-07-19 | Ventana Medical Systems, Inc. | Method for quantitating a protein by image analysis |
US6525046B1 (en) * | 2000-01-18 | 2003-02-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as antiinflammatory agents |
US7740841B1 (en) | 2000-01-28 | 2010-06-22 | Sunnybrook Health Science Center | Therapeutic method for reducing angiogenesis |
IL151045A0 (en) | 2000-02-07 | 2003-04-10 | Abbott Gmbh & Co Kg | 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors |
US6608052B2 (en) | 2000-02-16 | 2003-08-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as anti-inflammatory agents |
US6658473B1 (en) | 2000-02-25 | 2003-12-02 | Sun Microsystems, Inc. | Method and apparatus for distributing load in a computer environment |
ATE533056T1 (en) | 2000-03-02 | 2011-11-15 | Vegenics Pty Ltd | METHOD FOR FINDING TUMORS WHICH EXPRESS THE VASCULAR ENDOTHELIAL GROWTH FACTOR D |
DE60112268T2 (en) | 2000-03-06 | 2006-05-24 | Astrazeneca Ab | USE OF QUINAZOLIN DERIVATIVES AS INHIBITORS OF ANGIOGENESIS |
GB0005357D0 (en) | 2000-03-06 | 2000-04-26 | Smithkline Beecham Plc | Compounds |
US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
US6403588B1 (en) | 2000-04-27 | 2002-06-11 | Yamanouchi Pharmaceutical Co., Ltd. | Imidazopyridine derivatives |
US6390102B1 (en) | 2000-07-14 | 2002-05-21 | General Electric Company | Silicone compositions for personal care products and method for making |
US7175844B2 (en) | 2000-07-18 | 2007-02-13 | Joslin Diabetes Center, Inc. | Methods of modulating fibrosis |
JP2004504360A (en) | 2000-07-24 | 2004-02-12 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 1- (5-tert-butyl-2-P-tolyl-2H-pyrazol-3-yl) -3- [4- (2-morpholin-4-yl-ethoxy) -naphthalen-1-yl] -urea Improved oral formulation |
GT200100147A (en) | 2000-07-31 | 2002-06-25 | IMIDAZOL DERIVATIVES | |
AU2001284742A1 (en) | 2000-08-04 | 2002-02-18 | Loma Linda University | Iron regulating protein-2 (IRP-2) as a diagnostic for neurodegenerative disease |
AU2001283237B2 (en) | 2000-08-11 | 2007-09-20 | Vertex Pharmaceuticals Incorporated | Pyridine derivatives as inhibitors of p38 |
US20020173507A1 (en) | 2000-08-15 | 2002-11-21 | Vincent Santora | Urea compounds and methods of uses |
ES2261224T3 (en) | 2000-08-17 | 2006-11-16 | The Kitasato Institute | NEW DERIVATIVES OF PSEUDOERITROMICINA. |
AP2001002266A0 (en) | 2000-08-31 | 2001-09-30 | Pfizer Prod Inc | Pyrazole derivatives. |
AU2001291172A1 (en) | 2000-09-20 | 2002-04-02 | The President And Fellows Of Harvard College | Methods for the diagnosis of neoplastic disorders using angiogenin |
AUPR034000A0 (en) | 2000-09-25 | 2000-10-19 | Fujisawa Pharmaceutical Co., Ltd. | Aminoalcohol derivatives |
EP1415987B1 (en) | 2000-10-20 | 2007-02-28 | Eisai R&D Management Co., Ltd. | Nitrogenous aromatic ring compounds as anti cancer agents |
JP3768800B2 (en) | 2000-10-31 | 2006-04-19 | キヤノン株式会社 | Image forming apparatus |
AU2002223500A1 (en) | 2000-11-17 | 2002-05-27 | Novo-Nordisk A/S | Glucagon antagonists/inverse agonists |
MXPA03004583A (en) | 2000-11-27 | 2004-10-14 | Eric A Brill | System, method, and program for sorting objects. |
KR20050116401A (en) | 2000-11-28 | 2005-12-12 | 화이자 프로덕츠 인크. | Salts of a isothiazole-4-carboxamide and their use as anti-hyperproliferation agents |
WO2002044156A2 (en) | 2000-11-29 | 2002-06-06 | Glaxo Group Limited | Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors |
AU2002222589A1 (en) * | 2000-12-08 | 2002-06-18 | Kyowa Hakko Kogyo Co. Ltd. | Oral preprations having itching-relievign or antipruritic activity |
NZ526450A (en) | 2000-12-21 | 2005-04-29 | Pliva Istrazivacki Inst D | Macrolide antibiotics |
KR100362390B1 (en) | 2000-12-29 | 2002-11-23 | 삼성전자 주식회사 | Developing device-toner cartridge assembly for image forming apparatus |
US7235576B1 (en) * | 2001-01-12 | 2007-06-26 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
JP2004532187A (en) | 2001-01-25 | 2004-10-21 | ギルフォード ファーマシュウティカルズ インコーポレイテッド | Trisubstituted carbocyclic cyclophilin binding compounds and their uses |
WO2002059081A2 (en) | 2001-01-26 | 2002-08-01 | Kirin Beer Kabushiki Kaisha | Urea derivatives as inhibitors of ccr-3 receptor |
FR2820136A1 (en) | 2001-01-26 | 2002-08-02 | Aventis Pharma Sa | NOVEL UREA DERIVATIVES, PROCESS FOR THEIR PREPARATION, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF |
US6670364B2 (en) | 2001-01-31 | 2003-12-30 | Telik, Inc. | Antagonists of MCP-1 function and methods of use thereof |
PL414997A1 (en) | 2001-02-19 | 2016-02-29 | Novartis Ag | Application of 40-O-(2-hydroxyethyl)-rapamycin for treatment of solid kidney tumors |
UA76977C2 (en) | 2001-03-02 | 2006-10-16 | Icos Corp | Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers |
US6525091B2 (en) * | 2001-03-07 | 2003-02-25 | Telik, Inc. | Substituted diarylureas as stimulators for Fas-mediated apoptosis |
ES2286267T3 (en) | 2001-03-07 | 2007-12-01 | Telik, Inc. | DIARILURES REPLACED AS STIMULATORS OF MIDDLE PHAS. |
PT1370552E (en) | 2001-03-23 | 2007-04-30 | Bayer Pharmaceuticals Corp | Rho-kinase inhibitors |
ATE507839T1 (en) | 2001-04-02 | 2011-05-15 | Genentech Inc | COMBINATION THERAPY |
JP2005507367A (en) | 2001-04-13 | 2005-03-17 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 1,4-disubstituted benzofused compounds |
CA2490819A1 (en) | 2001-04-13 | 2002-10-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as anti-inflammatory agents |
US7371763B2 (en) | 2001-04-20 | 2008-05-13 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
JP4366936B2 (en) | 2001-04-20 | 2009-11-18 | バイエル コーポレイション | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridylurea |
US20030207914A1 (en) | 2001-04-20 | 2003-11-06 | Bayer Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
CA2445357A1 (en) | 2001-04-27 | 2002-11-07 | Vertex Pharmaceuticals Incorporated | Pyrazole derived kinase inhibitors |
EP1392661A1 (en) | 2001-05-16 | 2004-03-03 | Boehringer Ingelheim Pharmaceuticals Inc. | Diarylurea derivatives useful as anti-inflammatory agents |
US7411055B2 (en) * | 2001-05-25 | 2008-08-12 | Immunex Corporation | Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof |
WO2003004523A1 (en) | 2001-07-02 | 2003-01-16 | Bayer Aktiengesellschaft | Regulation of human citron rho/rac-interacting kinase |
DE60219793T2 (en) | 2001-07-11 | 2008-01-24 | Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield | Process for the treatment of cytokine-mediated diseases |
ES2393900T3 (en) | 2001-12-03 | 2012-12-28 | Bayer Healthcare Llc | Aryl urea compounds in combination with other cytostatic or cytotoxic agents for the treatment of human cancers |
US7307071B2 (en) | 2001-12-04 | 2007-12-11 | Onyx Pharmaceuticals, Inc | RAF-MEK-ERK pathway inhibitors to treat cancer |
AU2002353228B2 (en) | 2001-12-21 | 2008-09-11 | The Welcome Trust | Genes |
WO2003060111A2 (en) | 2001-12-24 | 2003-07-24 | Catalyst Biomedica Limited | Cancer-specific mutants of b-raf genes and uses thereof |
US20040096855A1 (en) | 2001-12-24 | 2004-05-20 | Michael Stratton | Genes |
US20030207872A1 (en) | 2002-01-11 | 2003-11-06 | Bayer Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US20080108672A1 (en) * | 2002-01-11 | 2008-05-08 | Bernd Riedl | Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors |
WO2003059373A2 (en) | 2002-01-16 | 2003-07-24 | Ramot At Tel Aviv University Ltd. | Compositions and their use for enhancing and inhibiting fertilization |
US6998391B2 (en) | 2002-02-07 | 2006-02-14 | Supergen.Inc. | Method for treating diseases associated with abnormal kinase activity |
US20040023961A1 (en) * | 2002-02-11 | 2004-02-05 | Bayer Corporation | Aryl ureas with raf kinase and angiogenisis inhibiting activity |
WO2003068229A1 (en) * | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
PT1580188E (en) | 2002-02-11 | 2012-01-25 | Bayer Healthcare Llc | Aryl ureas as kinase inhibitors |
US7645878B2 (en) * | 2002-03-22 | 2010-01-12 | Bayer Healthcare Llc | Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof |
US8299108B2 (en) | 2002-03-29 | 2012-10-30 | Novartis Ag | Substituted benzazoles and methods of their use as inhibitors of raf kinase |
SI1499311T1 (en) | 2002-03-29 | 2010-03-31 | Novartis Vaccines & Diagnostic | Substituted benzazoles and use thereof as raf kinase inhibitors |
DE10221524A1 (en) | 2002-05-14 | 2003-12-04 | Kmb Produktions Ag Felben | Method and device for producing consumer goods |
AU2003233576A1 (en) | 2002-05-17 | 2003-12-02 | Sugen, Inc. | Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals |
AR037647A1 (en) | 2002-05-29 | 2004-12-01 | Novartis Ag | USED DIARILUREA DERIVATIVES FOR THE TREATMENT OF DEPENDENT DISEASES OF THE PROTEIN KINase |
JP2005538975A (en) | 2002-07-03 | 2005-12-22 | アステックス テクノロジー リミテッド | 3- (Hetero) arylmethoxypyridines and their analogs as p38 MAP kinase inhibitors |
CN1678314A (en) | 2002-08-27 | 2005-10-05 | 默克专利有限公司 | Glycinamide derivatives as raf-kinase inhibitors |
NZ538513A (en) | 2002-09-05 | 2007-02-23 | Neurosearch As | Diarylurea derivatives and their use as chloride channel blockers |
JP4690889B2 (en) | 2002-10-24 | 2011-06-01 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Methylene urea derivative |
WO2004043374A2 (en) | 2002-11-06 | 2004-05-27 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for treating cancer using proteasome inhibitors |
RU2005118750A (en) | 2002-11-15 | 2006-03-20 | Новартис АГ (CH) | ORGANIC COMPOUNDS |
SE0203654D0 (en) | 2002-12-09 | 2002-12-09 | Astrazeneca Ab | New compounds |
US20030232400A1 (en) | 2002-12-20 | 2003-12-18 | Susan Radka | Methods of screening subjects for expression of soluble receptors of vascular endothelial growth factor (VEGF) for use in managing treatment and determining prognostic outcome |
US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
MXPA05009104A (en) | 2003-02-28 | 2006-05-31 | Bayer Pharmaceuticals Corp | Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders. |
WO2004078746A2 (en) | 2003-02-28 | 2004-09-16 | Bayer Pharmaceuticals Corporation | 2-oxo-1,3,5-perhydrotriazapine derivatives useful in the treatment of hyper-proliferative, angiogenesis, and inflammatrory disorders |
US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
WO2004078128A2 (en) | 2003-02-28 | 2004-09-16 | Bayer Pharmaceuticals Corporation | Substituted pyridine derivatives useful in the treatment of cancer and other disorders |
US7531553B2 (en) | 2003-03-21 | 2009-05-12 | Amgen Inc. | Heterocyclic compounds and methods of use |
JP2006521304A (en) | 2003-03-24 | 2006-09-21 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | Oxamide derivatives useful as raf kinase inhibitors |
WO2004084889A1 (en) | 2003-03-28 | 2004-10-07 | Pfizer Inc. | Use of protein kinase c inhibitor for suppressing sustained slow postsynaptic excitation (sspe) of enteric neurons |
US6896863B2 (en) | 2003-04-01 | 2005-05-24 | E. I. Du Pont De Nemours And Company | Sodium cyanide process |
ATE366108T1 (en) * | 2003-05-20 | 2007-07-15 | Bayer Pharmaceuticals Corp | DIARYL UREAS FOR PDGFR-MEDIATED DISEASES |
CA2527573A1 (en) | 2003-06-05 | 2004-12-16 | Warner-Lambert Company Llc | Cycloalkyl and heterocycloalkyl substituted benzothiophenes as therapeutic agents |
US20040259926A1 (en) | 2003-06-05 | 2004-12-23 | Bruendl Michelle M. | 3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents |
WO2005002673A1 (en) | 2003-07-03 | 2005-01-13 | Astex Therapeutics Limited | Raf kinase inhibitors |
CA2531485C (en) | 2003-07-07 | 2013-03-26 | Merck Patent Gmbh | Malonamide derivatives |
US20060173033A1 (en) | 2003-07-08 | 2006-08-03 | Michaela Kneissel | Use of rapamycin and rapamycin derivatives for the treatment of bone loss |
WO2005004864A1 (en) | 2003-07-11 | 2005-01-20 | Merck Patent Gmbh | Benzimidazole derivatives as raf kinase inhibitors |
WO2005016252A2 (en) | 2003-07-11 | 2005-02-24 | Ariad Gene Therapeutics, Inc. | Phosphorus-containing macrocycles |
ES2465624T3 (en) | 2003-07-11 | 2014-06-06 | Merck Patent Gmbh | Benzimidazole carboxamides as inhibitors of RAF kinase |
WO2005009367A2 (en) | 2003-07-17 | 2005-02-03 | Ambit Biosciences Corporation | Treatment of diseases with kinase inhibitors |
NZ580384A (en) | 2003-07-23 | 2011-03-31 | Bayer Pharmaceuticals Corp | 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions |
TW200523262A (en) | 2003-07-29 | 2005-07-16 | Smithkline Beecham Corp | Inhibitors of AKT activity |
DE10334663A1 (en) | 2003-07-30 | 2005-03-10 | Merck Patent Gmbh | urea derivatives |
JP2007502983A (en) * | 2003-08-15 | 2007-02-15 | ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | Multifactor assay for cancer detection |
WO2005027972A2 (en) | 2003-09-23 | 2005-03-31 | Novartis Ag | Combination of a vegf receptor inhibitor with a chemotherapeutic agent |
DE10344223A1 (en) | 2003-09-24 | 2005-04-21 | Merck Patent Gmbh | New 2-anilino-1,3-benzoxazole derivatives, are inhibitors of kinases, especially tyrosine- or Raf-kinases, useful e.g. for treating solid tumors, angiogenesis, diabetic retinopathy, inflammation or psoriasis |
US20080045546A1 (en) * | 2003-10-15 | 2008-02-21 | Axel Bouchon | Tetradydro-Naphthalene And Urea Derivatives |
ATE435015T1 (en) | 2003-10-16 | 2009-07-15 | Novartis Vaccines & Diagnostic | SUBSTITUTED BENZAZOLES AND THEIR USE AS RAF-KINASE INHIBITORS |
JP2007509059A (en) | 2003-10-16 | 2007-04-12 | カイロン コーポレイション | 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of Raf kinase for the treatment of cancer |
DE10349587A1 (en) | 2003-10-24 | 2005-05-25 | Merck Patent Gmbh | Benzimidazolylderivate |
US7767670B2 (en) | 2003-11-13 | 2010-08-03 | Ambit Biosciences Corporation | Substituted 3-carboxamido isoxazoles as kinase modulators |
DE10352979A1 (en) | 2003-11-13 | 2005-06-09 | Merck Patent Gmbh | Pyridopyrimidinone |
DE10354060A1 (en) | 2003-11-19 | 2005-06-02 | Merck Patent Gmbh | pyrrole |
AU2004296376B2 (en) | 2003-12-05 | 2010-03-04 | Bristol-Myers Squibb Company | Inhibitors of type 2 vascular endothelial growth factor receptors |
DE602004024115D1 (en) | 2003-12-09 | 2009-12-24 | Us Gov Health & Human Serv | METHOD FOR SUPPRESSING AN IMMUNE RESPONSE OR TREATING PROLIFERATIVE DISEASES |
US20070093529A1 (en) | 2003-12-10 | 2007-04-26 | Dirk Finsinger | Diacylhydrazine derivatives |
CA2548394A1 (en) | 2003-12-12 | 2005-06-30 | Bayer Pharmaceuticals Corporation | Methods for prediction and prognosis of cancer, and monitoring cancer therapy |
US20070161677A1 (en) | 2004-01-30 | 2007-07-12 | Merck Patent Gmbh | Bisarylurea derivatives |
WO2005089443A2 (en) | 2004-03-19 | 2005-09-29 | The Penn State Research Foundation | Combinatorial methods and compositions for treatment of melanoma |
JP2007535565A (en) * | 2004-04-30 | 2007-12-06 | バイエル ファーマシューティカルス コーポレーション | Substituted pyrazolyl urea derivatives useful for the treatment of cancer |
MY191349A (en) | 2004-08-27 | 2022-06-17 | Bayer Pharmaceuticals Corp | New pharmaceutical compositions for the treatment of hyper-proliferative disorders |
DE602005007048D1 (en) | 2004-08-27 | 2008-07-03 | Bayer Pharmaceuticals Corp | PHARMACEUTICAL COMPOSITIONS IN THE FORM OF SOLID DISPERSIONS FOR THE TREATMENT OF CANCER |
CA2578384A1 (en) | 2004-09-06 | 2006-03-16 | Altana Pharma Ag | Novel pyrazolopyrimidines |
JP5215666B2 (en) | 2004-09-29 | 2013-06-19 | バイエル・ファルマ・アクチェンゲゼルシャフト | Thermodynamically stable form of BAY 43-9006 tosylate |
JP2008514657A (en) | 2004-09-29 | 2008-05-08 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 4- {4-[({[4-Chloro-3- (trifluoromethyl) phenyl] amino} carbonyl) amino] phenoxy} -N-methylpyridine-2-carboxamide |
PL1858877T3 (en) | 2005-01-14 | 2014-08-29 | Gilead Connecticut Inc | 1,3 substituted diaryl ureas as modulators of kinase activity |
DE602006017188D1 (en) | 2005-03-07 | 2010-11-11 | Bayer Schering Pharma Ag | PHARMACEUTICAL COMPOSITION USING AN OMEGA CARBOXYARYL-SUBSTITUTED DIPHENYL HEAVEN IN THE TREATMENT OF CANCER |
DE102005015253A1 (en) | 2005-04-04 | 2006-10-05 | Merck Patent Gmbh | New pyrazole derivatives are tyrosine kinase inhibitors useful to treat e.g. solid tumors, diabetic retinopathy, age-related macular degeneration or inflammatory disease, osteoarthritis and rickets |
CA2609387A1 (en) | 2005-05-27 | 2006-11-30 | Bayer Healthcare Ag | Combination therapy comprising diaryl ureas for treating diseases |
MX2007014726A (en) | 2005-05-27 | 2008-02-14 | Bayer Healthcare Ag | Combination therapy comprising a diaryl urea compound and a pi3, akt kinase or mtor inhibitors (rapamycins) for cancer treatment. |
EP1937837A2 (en) | 2005-07-29 | 2008-07-02 | Siemens Healthcare Diagnostics Inc. | Methods and kits for the prediction of therapeutic success, recurrence free and overall survival in cancer therapies |
ATE493652T1 (en) * | 2005-08-11 | 2011-01-15 | Siemens Healthcare Diagnostics | QUANTITATIVE ASSAY FOR PDGFR BETA IN BODY FLUID |
AU2006298881A1 (en) | 2005-09-21 | 2007-04-12 | 4Sc Ag | Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors |
AU2006298882B2 (en) | 2005-09-21 | 2011-10-27 | 4Sc Ag | Novel sulphonylpyrroles as inhibitors of HDAC S novel sulphonylpyrroles |
KR20080073711A (en) | 2005-10-21 | 2008-08-11 | 바이엘 헬스케어 엘엘씨 | Methods for prediction and prognosis of cancer, and monitoring cancer therapy |
JP2009513707A (en) * | 2005-10-31 | 2009-04-02 | バイエル ヘルスケア リミティド ライアビリティ カンパニー | Diaryl urea and concomitant drugs |
US8329408B2 (en) | 2005-10-31 | 2012-12-11 | Bayer Healthcare Llc | Methods for prognosis and monitoring cancer therapy |
CA2627873A1 (en) | 2005-10-31 | 2007-05-10 | Scott Wilhelm | Treatment of cancer with sorafenib |
US20080311604A1 (en) | 2005-11-02 | 2008-12-18 | Elting James J | Methods for Prediction and Prognosis of Cancer, and Monitoring Cancer Therapy |
WO2007056011A2 (en) | 2005-11-02 | 2007-05-18 | Bayer Healthcare Llc | Methods for prediction and prognosis of cancer, and monitoring cancer therapy |
WO2007054216A1 (en) * | 2005-11-10 | 2007-05-18 | Bayer Healthcare Ag | Diaryl urea for treating pulmonary hypertension |
BRPI0618524A2 (en) | 2005-11-10 | 2011-09-06 | Bayer Schering Pharma Ag | use of diaryl ureas for the treatment of pulmonary hypertension, as well as the combination and composition comprising said diaryl ureas and the use of the combination |
MX2008006239A (en) | 2005-11-14 | 2008-12-12 | Bayer Healthcare Llc | Methods for prediction and prognosis of cancer, and monitoring cancer therapy. |
WO2007059155A1 (en) | 2005-11-14 | 2007-05-24 | Bayer Pharmaceuticals Corporation | Treatment of cancers having resistance to chemotherapeutic agents |
US20100144749A1 (en) * | 2005-11-14 | 2010-06-10 | Scott Wilhelm | Treatment of cancers with acquired resistance to kit inhibitors |
WO2007064872A2 (en) | 2005-12-01 | 2007-06-07 | Bayer Healthcare Llc | Urea compounds useful in the treatment of cancer |
JP2009524585A (en) * | 2005-12-15 | 2009-07-02 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | Diarylureas for treating viral infections |
US20090227637A1 (en) | 2005-12-15 | 2009-09-10 | Olaf Weber | Diaryl ureas for treating virus infections |
WO2007068380A1 (en) * | 2005-12-15 | 2007-06-21 | Bayer Healthcare Ag | Diaryl urea for treating virus infections |
JP5331485B2 (en) * | 2005-12-21 | 2013-10-30 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Substituted pyrimidine derivatives useful for the treatment of cancer and other disorders |
US20090197922A1 (en) | 2006-01-24 | 2009-08-06 | The University Of Chicago | Compositions and methods for treating pulmonary hypertension |
US8530493B2 (en) | 2006-02-22 | 2013-09-10 | 4Sc Ag | Indolopyridines as Eg5 kinesin modulators |
EA015151B1 (en) | 2006-02-22 | 2011-06-30 | 4ЭсЦэ АГ | Indolopyridines as eg5 kinesin modulators |
WO2007109571A2 (en) | 2006-03-17 | 2007-09-27 | Prometheus Laboratories, Inc. | Methods of predicting and monitoring tyrosine kinase inhibitor therapy |
JP2009532029A (en) | 2006-03-31 | 2009-09-10 | バイエル・ヘルスケア・エルエルシー | Cancer prediction and prognostic methods and cancer treatment monitoring |
EP2094268A2 (en) * | 2006-05-26 | 2009-09-02 | Bayer HealthCare, LLC | Drug combinations with substituted diaryl ureas for the treatment of cancer |
AR062927A1 (en) * | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4- ([[4- CHLORINE-3- (TRIFLUOROMETILE) PHENYL) CARBAMOIL] AMINO] -3- FLUOROPHENOXY) -N- METHYLPIRIDIN-2-MONOHIDRATED CARBOXAMIDE |
CA2668748A1 (en) * | 2006-11-09 | 2008-05-15 | Bayer Schering Pharma Aktiengesellschaft | Polymorph iii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide |
MX2009004861A (en) | 2006-11-09 | 2009-05-21 | Abbott Gmbh & Co Kg | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor. |
WO2008058644A1 (en) * | 2006-11-14 | 2008-05-22 | Bayer Schering Pharma Aktiengesellschaft | Polymorph ii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide |
US20100150863A1 (en) * | 2006-12-20 | 2010-06-17 | Bayer Pharmaceuticals Corporation | Hydroxy methyl phenyl pyrazolyl urea compound useful in treatment of cancer |
CA2673041A1 (en) | 2006-12-20 | 2008-07-03 | Bayer Healthcare Llc | 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl) phenyl]-1h-pyrazol-5-yl } carbamoyl)-amino] -3-fluorophenoxy} -n-methylpyridine-2-carboxamide as well as prodrugs and salts thereof for the treatment of cancer |
US8680124B2 (en) * | 2007-01-19 | 2014-03-25 | Bayer Healthcare Llc | Treatment of cancers with acquired resistance to kit inhibitors |
JP2010516692A (en) * | 2007-01-19 | 2010-05-20 | バイエル・ヘルスケア・エルエルシー | Treatment of cancer resistant to chemotherapeutic agents |
US8445687B2 (en) | 2007-09-10 | 2013-05-21 | Cipla Limited | Process for the preparation of a RAF kinase inhibitor and intermediates for use in the process |
WO2009054004A2 (en) | 2007-10-22 | 2009-04-30 | Natco Pharma Limited | Process for the preparation of sorafenib |
FR2929509B1 (en) * | 2008-04-02 | 2011-01-21 | Lvmh Rech | USE OF ALKYL GLYCOSIDES OR ALKYL GLYCOSIDE MIXTURES AS AGENTS FOR INHIBITING MICROBIAL GROWTH AND COMPOSITIONS CONTAINING SAID ALKYL GLYCOSIDES |
JP5432468B2 (en) | 2008-04-10 | 2014-03-05 | 光洋サーモシステム株式会社 | Horizontal furnace equipment |
US20110178137A1 (en) * | 2008-06-25 | 2011-07-21 | Bayer Schering Pharma Aktiengesellschaft | Diaryl urea for treating heart failure |
EP2350663A2 (en) * | 2008-10-21 | 2011-08-03 | Bayer HealthCare LLC | Identification of signature genes associated with hepatocellular carcinoma |
US8722715B2 (en) | 2008-11-07 | 2014-05-13 | NovaBay Pharmaceuticals | Antimicrobial oxazolidinone, hydantoin and imidazolidinone compositions |
KR101283904B1 (en) | 2009-04-16 | 2013-07-16 | 알까뗄 루슨트 | Method and apparatus for selecting object terminal in multiple base stations mimo system |
JP5821626B2 (en) | 2011-12-27 | 2015-11-24 | 富士ゼロックス株式会社 | Image forming apparatus and program |
-
2004
- 2004-05-19 AT AT04776037T patent/ATE366108T1/en active
- 2004-05-19 JP JP2006533210A patent/JP4860474B2/en active Active
- 2004-05-19 MX MXPA05012486A patent/MXPA05012486A/en active IP Right Grant
- 2004-05-19 CA CA2526617A patent/CA2526617C/en active Active
- 2004-05-19 PL PL04752642T patent/PL1636585T3/en unknown
- 2004-05-19 US US10/571,100 patent/US20070020704A1/en not_active Abandoned
- 2004-05-19 AT AT04752642T patent/ATE384264T1/en active
- 2004-05-19 JP JP2006533211A patent/JP2007511203A/en active Pending
- 2004-05-19 WO PCT/US2004/015655 patent/WO2004113274A2/en active IP Right Grant
- 2004-05-19 ES ES04776037T patent/ES2288694T3/en active Active
- 2004-05-19 CA CA2526636A patent/CA2526636C/en active Active
- 2004-05-19 WO PCT/US2004/015653 patent/WO2005000284A2/en active IP Right Grant
- 2004-05-19 EP EP04776037A patent/EP1626714B1/en active Active
- 2004-05-19 PT PT04752642T patent/PT1636585E/en unknown
- 2004-05-19 US US10/848,567 patent/US8796250B2/en active Active
- 2004-05-19 ES ES04752642T patent/ES2305808T3/en active Active
- 2004-05-19 DE DE602004011340T patent/DE602004011340T2/en active Active
- 2004-05-19 DE DE602004007382T patent/DE602004007382T2/en active Active
- 2004-05-19 PL PL04776037T patent/PL1626714T3/en unknown
- 2004-05-19 PT PT04776037T patent/PT1626714E/en unknown
- 2004-05-19 EP EP04752642A patent/EP1636585B2/en not_active Not-in-force
- 2004-05-19 DK DK04776037T patent/DK1626714T3/en active
- 2004-05-19 DK DK04752642T patent/DK1636585T3/en active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003068228A1 (en) * | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Aryl ureas with angiogenesis inhibiting activity |
Non-Patent Citations (1)
Title |
---|
WISSNER A ET AL: "ANALOGUES OF PLATELET ACTIVATING FACTOR. 7. BIS-ARYL AMIDE AND BIS-ARYL UREA RECEPTOR ANTAGONIST OF PAF" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 35, no. 26, 25 December 1992 (1992-12-25), pages 4779-4789, XP000676688 ISSN: 0022-2623 * |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US8841330B2 (en) | 1999-01-13 | 2014-09-23 | Bayer Healthcare Llc | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US7897623B2 (en) | 1999-01-13 | 2011-03-01 | Bayer Healthcare Llc | ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors |
US7838541B2 (en) | 2002-02-11 | 2010-11-23 | Bayer Healthcare, Llc | Aryl ureas with angiogenesis inhibiting activity |
US8618141B2 (en) | 2002-02-11 | 2013-12-31 | Bayer Healthcare Llc | Aryl ureas with angiogenesis inhibiting activity |
US8242147B2 (en) | 2002-02-11 | 2012-08-14 | Bayer Healthcare Llc | Aryl ureas with angiogenisis inhibiting activity |
US8110587B2 (en) | 2002-02-11 | 2012-02-07 | Bayer Healthcare Llc | Aryl ureas as kinase inhibitors |
US8796250B2 (en) | 2003-05-20 | 2014-08-05 | Bayer Healthcare Llc | Diaryl ureas for diseases mediated by PDGFR |
US8637553B2 (en) | 2003-07-23 | 2014-01-28 | Bayer Healthcare Llc | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
US8877933B2 (en) | 2004-09-29 | 2014-11-04 | Bayer Intellectual Property Gmbh | Thermodynamically stable form of a tosylate salt |
US8124782B2 (en) | 2004-09-29 | 2012-02-28 | Bayer Pharma Aktiengesellschaft | Process for the preparation of 4-{4-[({[4 chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methylpyridine-2-carboxamide |
WO2006034796A1 (en) * | 2004-09-29 | 2006-04-06 | Bayer Healthcare Ag | Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-n-methylpyridine-2-carboxamide |
US9737488B2 (en) | 2005-03-07 | 2017-08-22 | Bayer Healthcare Llc | Pharmaceutical composition for the treatment of cancer |
JP2009514909A (en) * | 2005-11-10 | 2009-04-09 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | Diarylureas for treating pulmonary hypertension |
JP2009514910A (en) * | 2005-11-10 | 2009-04-09 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | Diarylureas for treating pulmonary hypertension |
EP2338488A1 (en) | 2006-05-26 | 2011-06-29 | Bayer HealthCare, LLC | Drug combinations with substituted diaryl ureas for the treatment of cancer |
US9957232B2 (en) | 2006-10-11 | 2018-05-01 | Bayer Healthcare Llc | 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate |
US10662195B2 (en) | 2009-09-16 | 2020-05-26 | Celgene Car Llc | Protein kinase conjugates and inhibitors |
US8653304B2 (en) | 2009-09-30 | 2014-02-18 | Toray Industries, Inc. | 2,3-dihydro-1H-indene-2-yl urea derivative and pharmaceutical application of same |
US11542492B2 (en) | 2009-12-30 | 2023-01-03 | Celgene Car Llc | Ligand-directed covalent modification of protein |
WO2012012404A1 (en) | 2010-07-19 | 2012-01-26 | Bayer Healthcare Llc | Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
WO2013000909A1 (en) | 2011-06-28 | 2013-01-03 | Bayer Intellectual Property Gmbh | Topical ophthalmological pharmaceutical composition containing sorafenib |
CN104302633A (en) * | 2012-05-18 | 2015-01-21 | 赛诺菲 | Benzo[1,3]dioxine derivatives and their use as LPAR5 antagonists |
RU2647727C2 (en) * | 2012-05-18 | 2018-03-19 | Санофи | Benzo[1,3]dioxin derivatives and their use as lpar5 antagonists |
AU2013261719B2 (en) * | 2012-05-18 | 2017-07-27 | Sanofi | Benzo[1,3]dioxine derivatives and their use as LPAR5 antagonists |
US9221784B2 (en) | 2012-05-18 | 2015-12-29 | Sanofi | Benzo[1,3]dioxine derivatives and their use as LPAR5 antagonists |
WO2013171318A1 (en) * | 2012-05-18 | 2013-11-21 | Sanofi | Benzo[1,3]dioxine derivatives and their use as lpar5 antagonists |
WO2017151044A1 (en) | 2016-03-02 | 2017-09-08 | Medivir Ab | Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine |
IT202000022636A1 (en) | 2020-09-25 | 2022-03-25 | Ente Ospedaliero Specializzato In Gastroenterologia Istituto Nazionale Di Ricovero E Cura A Caratter | “COMBINATION THERAPY OF SORAFENIB AND/OR REGORAFENIB WITH THE RECOMBINANT HUMAN PROTEOGLYCAN-4 PROTEIN FOR THE TREATMENT OF HEPATOCARCINOMA” |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1626714B1 (en) | Diaryl ureas for diseases mediated by pdgfr | |
US20080045589A1 (en) | Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer | |
ES2219670T3 (en) | USE OF PIRAZOLA COMPOUNDS FOR THE TREATMENT OF GLOMERULONEFRITIS, CANCER, ATEROSCLEROSIS OR RESTENOSIS. | |
CN102712601A (en) | A compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent | |
CN103974955B (en) | Pyrimido-pyridazinone compound and application thereof | |
AU2007220039A1 (en) | Inhibitors of the unfolded protein response and methods for their use | |
Qiu et al. | Exploration of 2-((pyridin-4-ylmethyl) amino) nicotinamide derivatives as potent reversal agents against P-glycoprotein-mediated multidrug resistance | |
JP6158892B2 (en) | 1,4-Benzodiazepine-2,5-dione and related compounds having therapeutic properties | |
WO2012012404A1 (en) | Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions | |
EP3227296B1 (en) | A deuterated triazolopyridazine as a kinase modulator | |
Li et al. | Imidazo [1, 2-a] pyridine derivatives as novel dual-target inhibitors of ABCB1 and ABCG2 for reversing multidrug resistance | |
CZ20014343A3 (en) | Pyrazinone derivatives | |
EA032697B1 (en) | Amidoheteroaryl aroyl hydrazide ethynes | |
Chamariya et al. | Role of KSP inhibitors as anti-cancer therapeutics: an update | |
JP2004532241A (en) | Phthalazine derivative having angiogenesis inhibitory activity | |
CN101501004A (en) | Compounds and compositions as HEDGEHOG signaling pathway modulators | |
CN109942562A (en) | Five-ring heterocycles connection compound in triazine class containing heteroaryl structure and its preparation method and application | |
JP2009234949A (en) | Plk-1 inhibitor | |
MXPA05012491A (en) | Diaryl ureas with kinase inhibiting activity | |
KR20060033817A (en) | Novel 3-(2-amino-6-pyridinyl)-4-hydroxyphenyl ketone derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/012486 Country of ref document: MX Ref document number: 2006533210 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2526636 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004776037 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004776037 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2004776037 Country of ref document: EP |